
Obesity and social network influence in inflammatory biomarkers in a general youth population

Dina B. Stensen, MD^{1,2,†}, Rafael A. Nozal Cañadas, MSc³, Christopher Sivert Nielsen, PhD^{4,5}, Anne Merethe Hanssen, PhD⁶, Lars Ailo Bongo, PhD³, Anne-Sofie Furberg, PhD^{7,8}

¹ Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway

² Division of Internal Medicine, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway

³ Department of Computer Science, UiT The Arctic University of Norway, Hansine Hansens veg 54, 9019 Tromsø, Norway

⁴ Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Marcus Thranes gate 6, 0473 Oslo, Norway

⁵ Department of Pain Management and Research, Division of Emergencies and Critical Care, Oslo University Hospital, Postboks 4956 Nydalen, 0424 Oslo, Norway

⁶ Department of Pain Management and Research, Division of Emergencies and Critical Care, Oslo University Hospital, Postboks 4956 Nydalen, 0424 Oslo, Norway




⁷ Department of Microbiology and Infection Control, Division of Internal Medicine, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway

⁸ Faculty of Health and Social Sciences, Molde University College, Britvegen 2, 6410 Molde, Norway

[†] Corresponding author: dina.b.stensen@uit.no

March 4, 2022

Notes

	We should delete this section eventually	12
	I don't like this part	13
	Maybe this can go to page 4	13

List of Figures

1	Overview of all biomarkers differences with respect sex. In many cases there is a significant difference between men and women ($p < 0.05$). Due biological reasons.	6
---	--	---

2	Overview of all subject (n=1038) biomarkers values with respect LOD levels. Most of the collected values are well above the LOD (blue).	8
3	A majestic grizzly bear	13
4	Overview of all antropometric variables differences with respect sex.	20

List of Tables

1	Sex differences for antropometry variables	6
2	Sex differences for all categorical host factor	7
3	Biomarkers that are statistically significant for either men or women, after Benjamini correction	9
4	Biomarkers that are statistically significant for either men or women, after Bonferroni correction	10
5	Biomarkers that are statistically significant with respect the antropometry variables in men, after applying Bonferroni correction	11
6	Biomarkers that are statistically significant with respect the antropometry variables in women, after applying Bonferroni correction	11
7	Biomarkers that are statistically significant with respect the blood variables in men, after applying Bonferroni correction. Non-significant values appears as a white space for easy reading.	12
8	Biomarkers that are statistically significant with respect the blood variables in women, after applying Bonferroni correction. Non-significant values appears as a white space for easy reading.	12
9	Example table	14
10	Summary of all biomarkers	15
11	Sex differences for each biomarker	16
12	Sex differences for Sex	17
13	Sex differences for GeneralHealth	17
14	Sex differences for BMICategorical	17
15	Sex differences for Smoke	17
16	Sex differences for Snuff	17
17	Sex differences for Alcohol	17
18	Sex differences for SportsLeisure	17
19	Sex differences for SummerTransport	18
20	Sex differences for WinterTransport	18
21	Sex differences for ScreenTime	18
22	Sex differences for LeanFishFrequency	18
23	Sex differences for FatFishFrequency	18
24	Sex differences for CheeseFrequency	18
25	Sex differences for ChocolateFrequency	18
26	Sex differences for FruitsFrequency	19
27	Sex differences for VegetablesFrequency	19
28	Sex differences for DairyFrequency	19
29	Sex differences for FruitJuiceFrequency	19
30	Sex differences for SugarJuiceFrequency	19
31	Sex differences for SugarDrinkFrequency	19
32	Sex differences for SweetenerDrinkFrequency	19
33	Sex differences for WaterFrequency	20
34	Sex differences for HighSchool	20
35	Summary of all blood variables	21
36	Biomarkers that are statistically significant for either men or women (1 of 8) .	22
37	Biomarkers that are statistically significant for either men or women (2 of 8) .	23
38	Biomarkers that are statistically significant for either men or women (3 of 8) .	24
39	Biomarkers that are statistically significant for either men or women (4 of 8) .	25
40	Biomarkers that are statistically significant for either men or women (5 of 8) .	26
41	Biomarkers that are statistically significant for either men or women (6 of 8) .	27
42	Biomarkers that are statistically significant for either men or women (7 of 8) .	28
43	Biomarkers that are statistically significant for either men or women (8 of 8) .	29

1 Abstract

1.1 Methods

The Fit Futures 1 study collected interview data on social contact among 1038 first level students in the same high school district in Norway. In this context, we also collected blood samples ($n = 937$), OLINK inflammatory proteomic data ($n = 936$) and did antropomorphic measurements ($n = 1034$). Social networks were constructed from self-reported social contact between participants.

All statistics summary things goes here.

1.2 Findings

There is an association between lifestyle factors, diseases, vitamim D levels and social interaction with several biomarkers.

1.3 Interpretation

We found results that might suggest that people in your social network may influence your inflammatory response.

1.4 Funding

The Northern Norway regional Health Authorities (grant number HNF1457-19) funded this study.

2 Introduction

Obesity is a condition associated with several health problems including the number one cause of death in almost every socio-economic group, cardiovascular diseases, as well as many types of cancers and other complications.

While there are genetic conditions associated with it, the most common causes of obesity are excessive food consumption or a lack of exercise. In simple terms your amount of body fat is simply the difference between your energy intake and energy output. These two factors are heavily influenced by your lifestyle, which in term are impacted by your friends. Obesity, despite not been caused by a viral, bacterial, or parasitic agent, is nevertheless contagious among close group of friends [1]. Even though it is impossible for an individual to perform lipogenesis with what somebody else eats, people tend to behave in the same way to their peers, and end up eating and exercising similarly as their direct contact network.

Obesity is associated with the inflammatory response of your immune system. While the exact mechanism is unclear, it might be due that a poor immune response that otherwise would have curled the infiltration of opportunistic bacteria, thus causing an unwelcome inflammatory response. In this study we explore the possibility that people in the same social network can influence your influence response, as well as how much these biomarkers are expressed with respect to your anthropometric variables. Answering two fundamental questions:

- Does the spread of levels of obesity also spread the biomarkers levels?
- How does the average proteomic profile compare between different categories of obesity?

3 Methods

3.1 Population and study design

The Tromsø Study Fit Futures 1 (TFF1) is a health survey conducted from 2010 to 2011 in the duration of 8 months. All first-year high school students in the municipalities of Tromsø and Balsfjord, Norway were invited. TFF1 included students from eight schools consecutively. A total of 1117 youths were invited and 93% attended, 508 girls and 530 boys.

Participants had a one-day visit at The Clinical Research Unit at the University Hospital of North Norway (UNN), including clinical examinations, microbiological samples, blood samples, a web-based general questionnaire, and an interview [2]. All procedures were performed by trained research nurses.

3.2 Host risk factors

Height and weight were measured on an electronic scale with participants wearing light clothing and no footwear. BMI was calculated as weight (kg) divided by the squared height (m^2). From the web-based questionnaire we got information about lifestyle including, sex, age, type of studies and recreational physical activity.

HERE SOME INFORMATION ABOUT HOW THE BLOOD WAS EXTRACTED IS MISSING.

3.3 Olink Target 96 Inflammation

The 92 bioarkers were analyzed at the Clinical Biomarkers Facility, SciLifeLab, (Uppsala, Sweden), using the Target 96 Inflammation panel from OLINK Holding AB (Uppsala, Sweden) [3]. From these 92 biomarkers we have two different values. The LOD (Limit of Detection) value, and the NDL (I still don't know what NDL actually means) value. The LOD level is the lowest value that can be detected, so any number lower than that is censored to the left. The NDL is the real value measured by the machine and can be under the LOD level. When this happens, it cannot be guaranteed that the value is correct.

All the biomarkers detailed information, can be found in 10 on page 15.

3.4 Social network analysis

The social network was constructed based on the following question in the interview: "Which students have you had most contact with the last week? Name up to 5 students at your own school or other schools in Tromsø and Balsfjord.". Reciprocity in the nomination was not mandatory. For each of the nominations, five "yes/no" questions assessed the type of contact they had with their nominations: "Do you have physical contact?", "Are you together at school?", "Are you together at sports?", "Are you together at home?", "Are you together at other places?". This resulted in five social networks: Physical Network, School Network, Sport Network, Home Network, and Other Network (Supplementary Figure 2). Adding all the relationships together formed a sixth network that was called the Overall Network. To evaluate if the friends mentioned were representative for the participants' social network, the following question was asked: "To what degree does this table of friends give an overview of your social network? Please indicate on a scale from 0 (small degree) to 10 (high degree)." Nominated friends that did not participate in TFF1 were excluded from the analysis (n=134). Each student is represented by one node in the network. Each relationship is represented by an undirected edge, i.e., line, in the network.

3.5 Statistical analysis

3.5.1 Software

Statistical analyses was performed by using R version 3.6.3 and R Studio 1.3.1093. Noticeable libraries were "igraph" [4] "statnet" (sna, ergm) [5] for linear autocorrelation and ERGM analysis, and "ggraph" [6] for display of results.

3.5.2 Host factors

For the evaluation of host risk factors for any categorical data, we applied Xi-square test, with Yates's correction for 2x2 tables and Fisher correction when applicable. In all cases, all the assumptions for the Xi-square test applied.

3.5.3 Social influence

PROPER CITATIONS HERE

The connection between nodes was analyzed using ERGM or Additive and Multiplicative Effects models (Supplementary Table 1 and Supplementary Figure 5). Patterns of connections (non-carriers connected to non-carriers, non-carriers connected to carriers, carriers connected to carriers) were analyzed by using Simulation Investigation for Empirical Network Analysis, an autocorrelation model [28] (Table 5). Further analysis was done with bootstrapping simulated networks against the observed network (Tables 2, 3 and Supplementary Table 2), descriptive analysis (Supplementary Table 3), and logistic regression (Supplementary Table 4, Figure 4). The mathematical background for the statistical methods is described in the supplementary material.

3.5.4 Ethics

A declaration of consent was signed by each participant in TFF1, participants younger than 16 years of age had to bring written consent from a parent or guardian. TFF1 was approved by The Regional Committee of Medical and Health Research Ethics (REK) and the Norwegian Data Protection Authority. The present study was approved by REK North, reference 2018/1975/REK Nord.

4 Results

4.1 Host factors

There are 3 major groups of variables that we are studying:

- **Antropometric variables:** Waist and hip circumference (cm), height (cm), weight (kg), BMI (kg/m^2), heart rate (bpm), systolic and diastolic blood pressure (mmHg)
- **Questionary data:** Sex, self reported general health, recreational drugs frequency (cigarettes, snuff and alcohol), frequency of sport activity outside school hours, method of transportation to and from school during summer and winter, screen time (computer, tv, mobile phone or tablet), frequency of dietary habits (lean fish, fat fish, cheese, chocolate, fruits, vegetables, dairy products, fruit juice without sugar, fruit juice with sugar, other sugar drinks, water) and highschool affiliation.
- **Staphylococcus Aureus carrier status:** We measure the carrier status in the nose and throat, with both a direct culture and enrich broth (REFERENCE TO THE SA Study here)
- **Blood variables:** Please refer to supplementary table for a detailed summary

4.2 Summary statistics

4.2.1 Sex differences

Men and women have different biological processes that affect the biomarkers levels, regardless of their social network or their current health status. This is appreciated in figure 1 and supplementary table 11 where we provide an overview of all biomarkers with respect sex. Because the difference between sex is sustancial, we stratified the analysis with respect sex.




Figure 1: Overview of all biomarkers differences with respect sex. In many cases there is a significant difference between men and women ($p < 0.05$). Due biological reasons.

Furthermore, we can also appreciate the antropometric differences in waist perimeter, height, and weight, in table 1 and supplementary figure 4 .

Concept	\bar{x}_{men}	\bar{x}_{women}	SD_{men}	SD_{women}	Significance
Waist	82.4	77.8	11.7	10.8	***
Hip	97.8	98.1	8.8	8.3	ns
Height	176.9	164.7	6.6	6.6	***
Weight	70.6	61.4	14.6	12.2	***
BMI	22.5	22.6	4.2	4.2	ns
HR	76.2	74.9	13.3	12.4	ns
SYSBP	117.4	118.1	12.8	12.9	ns
DIABP	63.5	63.5	8.1	7.4	ns

Table 1: Sex differences for antropometry variables

There are also some significant differences between each of the categorical variables in the host factor, summarized in 2 , detailed information for each variable can be found in tables across supplementary chapter 7.3.

Finally, summarized information about the blood data can be found in 7.4.

4.2.2 LOD vs NDL

In figure 2 we see an overview of all biomarkers levels. Since most of the collected values are well above the LOD, we decided to run all the analysis usind the NDL values. However, please

Variable	p-value	Significance
GeneralHealth	7.52e-01	ns
BMICategorical	1.49e-01	ns
Smoke	1.07e-01	ns
Snuff	1.88e-03	**
Alcohol	1.08e-02	*
SportsLeisure	6.46e-11	****
SummerTransport	3.40e-02	*
WinterTransport	3.63e-01	ns
ScreenTime	9.56e-02	ns
LeanFishFrequency	4.71e-01	ns
FatFishFrequency	3.93e-01	ns
CheeseFrequency	7.37e-01	ns
ChocolateFrequency	5.98e-01	ns
FruitsFrequency	3.98e-01	ns
VegetablesFrequency	9.90e-01	ns
DairyFrequency	7.74e-01	ns
FruitJuiceFrequency	6.46e-02	ns
SugarJuiceFrequency	5.77e-01	ns
SugarDrinkFrequency	9.97e-01	ns
SweetenerDrinkFrequency	4.61e-01	ns
WaterFrequency	3.91e-01	ns
HighSchool	5.98e-16	****
D_NasalCarrier	1.90e-05	****
D_ThroatCarrier	2.22e-03	**
E_NasalCarrier	2.96e-04	***
E_ThroatCarrier	9.95e-07	****

Table 2: Sex differences for all categorical host factor

notice that for biomarkers with very high proportion of Under LOD values, the result of the analysis is not guaranteed.




Figure 2: Overview of all subject ($n=1038$) biomarkers values with respect LOD levels. Most of the collected values are well above the LOD (blue).

4.3 Biomarkers

In this section, we show all different test done for each host factor with respect the 92 biomarkers.

4.3.1 Categorical host factors and biomarkers

We performed simple t-testing to find out if there is any association between the categorical data in the host factors and the biomarkers. In this section we only show the results that are statistically significant for either men or women, corrected for both Benjamini in table 3 and Bonferroni in table 4. You can find results that weren't corrected in supplementary materials in section 7.5.

4.3.2 Antropometry and biomarkers

We performed simple F-statistics againsts all antropometric variables. Only values significant after bonferroni are shown.

4.3.3 Blood and biomarkers

Same as before, we performed simple F-statistics againsts all numerical variables related with blood. Only values significant after bonferroni are shown.

Variable	Biomarker	Men	Women
GeneralHealth	Leukemia inhibitory factor	*	ns
BMICategorical	C-C motif chemokine 3	***	ns
BMICategorical	CUB domain-containing protein 1	****	****
BMICategorical	Macrophage colony-stimulating factor 1	*	**
BMICategorical	Fibroblast growth factor 21	**	*
BMICategorical	Glial cell line-derived neurotrophic factor	**	ns
BMICategorical	Hepatocyte growth factor	****	**
BMICategorical	Interleukin-18	**	**
BMICategorical	Interleukin-18 receptor 1	****	****
BMICategorical	Interleukin-6	**	****
BMICategorical	Monocyte chemotactic protein 3	****	****
BMICategorical	Matrix metalloproteinase-1	*	ns
BMICategorical	Stem cell factor	****	ns
BMICategorical	Tumor necrosis factor receptor superfamily member 9	**	ns
Smoke	Matrix metalloproteinase-10	*	ns
Snuff	Adenosine Deaminase	*	ns
Snuff	Fractalkine	*	ns
Snuff	Fibroblast growth factor 21	*	*
Snuff	Stem cell factor	*	**
Alcohol	Delta and Notch-like epidermal growth factor-related receptor	**	ns
Alcohol	Fibroblast growth factor 21	*	ns
SportsLeisure	Adenosine Deaminase	*	**
SportsLeisure	C-C motif chemokine 19	*	ns
SportsLeisure	Delta and Notch-like epidermal growth factor-related receptor	*	ns
SportsLeisure	Fibroblast growth factor 21	****	****
SportsLeisure	Urokinase-type plasminogen activator	*	*
SummerTransport	Interleukin-4	****	ns
WinterTransport	C-C motif chemokine 19	*	ns
FatFishFrequency	Fractalkine	*	ns
FatFishFrequency	Hepatocyte growth factor	*	ns
FatFishFrequency	Stem cell factor	***	ns
FatFishFrequency	Tumor necrosis factor	*	ns
FruitsFrequency	Interleukin-13	*	ns
VegetablesFrequency	Stem cell factor	*	ns
DairyFrequency	Interleukin-20 receptor subunit alpha	**	ns
WaterFrequency	Interleukin-4	*	ns
HighSchool	Adenosine Deaminase	*	ns
HighSchool	Fractalkine	**	ns
HighSchool	C-X-C motif chemokine 10	*	ns
HighSchool	Delta and Notch-like epidermal growth factor-related receptor	***	ns
HighSchool	Fibroblast growth factor 21	***	***
HighSchool	Fibroblast growth factor 23	**	ns
HighSchool	Interleukin-2	**	ns
HighSchool	Leukemia inhibitory factor receptor	*	ns
HighSchool	Osteoprotegerin	**	ns
HighSchool	Tumor necrosis factor ligand superfamily member 14	*	ns
HighSchool	Urokinase-type plasminogen activator	**	**
E_NasalCarrier	Tumor necrosis factor receptor superfamily member 9	*	ns
GeneralHealth	Matrix metalloproteinase-1	ns	*
BMICategorical	Delta and Notch-like epidermal growth factor-related receptor	ns	**
BMICategorical	Interleukin-10 receptor subunit beta	ns	**
BMICategorical	Monocyte chemotactic protein 4	ns	**
BMICategorical	TNF-related apoptosis-inducing ligand	ns	*
BMICategorical	Vascular endothelial growth factor A	ns	****
Smoke	Adenosine Deaminase	ns	*
Smoke	Delta and Notch-like epidermal growth factor-related receptor	ns	**
Smoke	Fibroblast growth factor 21	ns	***
Smoke	Leukemia inhibitory factor receptor	ns	***
Smoke	Stem cell factor	ns	***
Smoke	Urokinase-type plasminogen activator	ns	****
Snuff	Glial cell line-derived neurotrophic factor	ns	*
Snuff	Urokinase-type plasminogen activator	ns	**
Alcohol	Fibroblast growth factor 5	ns	*
Alcohol	Leukemia inhibitory factor receptor	ns	*
Alcohol	Urokinase-type plasminogen activator	ns	**
SportsLeisure	Interleukin-6	ns	**
LeanFishFrequency	Fibroblast growth factor 21	ns	**
CheeseFrequency	Stem cell factor	ns	*
ChocolateFrequency	Interleukin-2	ns	*
ChocolateFrequency	Leukemia inhibitory factor receptor	ns	**
FruitJuiceFrequency	Neurotrophin-3	ns	****
FruitJuiceFrequency	Stem cell factor	ns	*
SweetenerDrinkFrequency	Neurotrophin-3	ns	***
HighSchool	Interleukin-6	ns	*
HighSchool	Monocyte chemotactic protein 1	ns	*
HighSchool	Stem cell factor	ns	*

Table 3: Biomarkers that are statistically significant for either men or women, after Benjamini correction

Variable	Biomarker	Men	Women
GeneralHealth	Leukemia inhibitory factor	*	ns
BMICategorical	C-C motif chemokine 3	***	ns
BMICategorical	CUB domain-containing protein 1	****	****
BMICategorical	Macrophage colony-stimulating factor 1	*	*
BMICategorical	Fibroblast growth factor 21	**	ns
BMICategorical	Glial cell line-derived neurotrophic factor	**	ns
BMICategorical	Hepatocyte growth factor	****	**
BMICategorical	Interleukin-18	**	*
BMICategorical	Interleukin-18 receptor 1	****	****
BMICategorical	Interleukin-6	**	****
BMICategorical	Monocyte chemotactic protein 3	****	****
BMICategorical	Matrix metalloproteinase-1	*	ns
BMICategorical	Stem cell factor	****	ns
BMICategorical	Tumor necrosis factor receptor superfamily member 9	**	ns
Smoke	Matrix metalloproteinase-10	*	ns
Snuff	Adenosine Deaminase	*	ns
Snuff	Fractalkine	*	ns
Alcohol	Delta and Notch-like epidermal growth factor-related receptor	**	ns
SportsLeisure	C-C motif chemokine 19	*	ns
SportsLeisure	Fibroblast growth factor 21	****	*
SportsLeisure	Urokinase-type plasminogen activator	*	ns
SummerTransport	Interleukin-4	****	ns
WinterTransport	C-C motif chemokine 19	*	ns
FatFishFrequency	Hepatocyte growth factor	*	ns
FatFishFrequency	Stem cell factor	***	ns
FatFishFrequency	Tumor necrosis factor	*	ns
FruitsFrequency	Interleukin-13	*	ns
DairyFrequency	Interleukin-20 receptor subunit alpha	**	ns
HighSchool	Fractalkine	**	ns
HighSchool	C-X-C motif chemokine 10	*	ns
HighSchool	Delta and Notch-like epidermal growth factor-related receptor	***	ns
HighSchool	Fibroblast growth factor 21	***	***
HighSchool	Fibroblast growth factor 23	**	ns
HighSchool	Interleukin-2	**	ns
HighSchool	Leukemia inhibitory factor receptor	*	ns
HighSchool	Osteoprotegerin	**	ns
HighSchool	Tumor necrosis factor ligand superfamily member 14	*	ns
HighSchool	Urokinase-type plasminogen activator	**	*
GeneralHealth	Matrix metalloproteinase-1	ns	*
BMICategorical	Delta and Notch-like epidermal growth factor-related receptor	ns	**
BMICategorical	Interleukin-10 receptor subunit beta	ns	**
BMICategorical	Monocyte chemotactic protein 4	ns	**
BMICategorical	TNF-related apoptosis-inducing ligand	ns	*
BMICategorical	Vascular endothelial growth factor A	ns	****
Smoke	Delta and Notch-like epidermal growth factor-related receptor	ns	*
Smoke	Fibroblast growth factor 21	ns	**
Smoke	Leukemia inhibitory factor receptor	ns	***
Smoke	Stem cell factor	ns	***
Smoke	Urokinase-type plasminogen activator	ns	****
Snuff	Glial cell line-derived neurotrophic factor	ns	*
Snuff	Stem cell factor	ns	*
Snuff	Urokinase-type plasminogen activator	ns	*
Alcohol	Fibroblast growth factor 5	ns	*
Alcohol	Urokinase-type plasminogen activator	ns	**
SportsLeisure	Adenosine Deaminase	ns	**
SportsLeisure	Interleukin-6	ns	**
LeanFishFrequency	Fibroblast growth factor 21	ns	*
ChocolateFrequency	Interleukin-2	ns	*
ChocolateFrequency	Leukemia inhibitory factor receptor	ns	*
FruitJuiceFrequency	Neurotrophin-3	ns	****
SweetenerDrinkFrequency	Neurotrophin-3	ns	***
HighSchool	Monocyte chemotactic protein 1	ns	*

Table 4: Biomarkers that are statistically significant for either men or women, after Bonferroni correction

Protein	Waist	Hip	Height	Weight	BMI	HR	SYSBP	DIABP
C-C motif chemokine 3	****	**	ns	***	***	ns	ns	ns
C-C motif chemokine 4	**	ns	ns	ns	ns	ns	ns	ns
CUB domain-containing protein 1	****	****	ns	****	****	ns	ns	ns
Macrophage colony-stimulating factor 1	**	****	ns	***	***	ns	ns	ns
Delta and Notch-like epidermal growth factor-related receptor	*	*	ns	**	*	ns	ns	ns
Fibroblast growth factor 19	ns	ns	ns	ns	*	ns	ns	ns
Fibroblast growth factor 21	****	**	ns	*	**	ns	ns	ns
Glial cell line-derived neurotrophic factor	**	ns	ns	*	**	ns	ns	ns
Hepatocyte growth factor	****	***	ns	****	****	ns	ns	ns
Interleukin-18	***	****	ns	***	***	ns	ns	ns
Interleukin-18 receptor 1	****	****	ns	****	****	ns	ns	ns
Interleukin-20	ns	****	ns	**	ns	ns	ns	ns
Interleukin-6	****	***	ns	****	****	ns	ns	ns
Monocyte chemotactic protein 3	****	****	ns	****	****	ns	ns	ns
Stem cell factor	****	****	ns	****	****	ns	ns	ns
Signaling lymphocytic activation molecule	ns	ns	*	ns	ns	ns	ns	ns
Tumor necrosis factor receptor superfamily member 9	***	ns	ns	*	**	ns	ns	ns

Table 5: Biomarkers that are statistically significant with respect the antropometry variables in men, after applying Bonferroni correction

Protein	Waist	Hip	Height	Weight	BMI	HR	SYSBP	DIABP
Caspase-8	*	***	ns	***	***	ns	ns	ns
C-C motif chemokine 3	*	ns	ns	*	ns	ns	ns	ns
CUB domain-containing protein 1	****	****	ns	****	****	ns	ns	ns
Macrophage colony-stimulating factor 1	****	***	ns	**	**	ns	ns	ns
Delta and Notch-like epidermal growth factor-related receptor	ns	ns	ns	*	*	ns	ns	ns
Fibroblast growth factor 21	*	*	ns	ns	*	ns	ns	ns
Hepatocyte growth factor	****	***	ns	**	****	ns	ns	ns
Interleukin-10 receptor subunit beta	****	*	ns	**	**	ns	ns	ns
Interleukin-18	**	*	ns	*	**	ns	ns	ns
Interleukin-18 receptor 1	****	***	ns	***	****	ns	ns	ns
Interleukin-2	*	ns	ns	ns	ns	ns	ns	ns
Interleukin-6	****	****	ns	****	****	ns	ns	ns
Interleukin-7	**	**	ns	**	*	ns	ns	ns
Monocyte chemotactic protein 3	****	****	ns	****	****	ns	ns	ns
Monocyte chemotactic protein 4	*	ns	ns	ns	*	ns	ns	ns
Latency-associated peptide transforming growth factor beta-1	*	*	ns	ns	ns	ns	ns	ns
TNF-related apoptosis-inducing ligand	**	*	ns	ns	*	ns	ns	ns
TNF-related activation-induced cytokine	*	**	ns	*	ns	ns	ns	ns
Vascular endothelial growth factor A	**	*	ns	*	****	ns	ns	ns

Table 6: Biomarkers that are statistically significant with respect the antropometry variables in women, after applying Bonferroni correction

Protein	Fe	Tyglipides	HDL	hs-CRP	APO A	APO B	Estradiol	Testosterone	Albumin	FA C15:0	FA C16:0	FA C16:1 n-7	FA C18:1 n-9	FA C20:3 n-6	wFA C12:0	wFA C15:0	wFA C18:0	wFA C24:0
Adenosine Deaminase								*										
C-C motif chemokine 20		***																
Macrophage colony-stimulating factor 1	**			*														
C-X-C motif chemokine 9				*														
Fibroblast growth factor 5										*	**			*				
Interleukin-18 receptor 1								*										
Interleukin-20						**	****											
Interleukin-22 receptor subunit alpha-1																		*
Interleukin-6	**			*														
Leukemia inhibitory factor																	*	
Monocyte chemoattractant protein 1			*															
Oncostatin-M				*														
Programmed cell death 1 ligand 1												*						
Stem cell factor			**	*	**					**								
Tumor necrosis factor																		
Tumor necrosis factor receptor superfamily member 9														**				
TNF-related activation-induced cytokine																	*	

Table 7: Biomarkers that are statistically significant with respect the blood variables in men, after applying Bonferroni correction. Non-significant values appears as a white space for easy reading.

Protein	WCE	WCE	WCE	Fe	Tyglipides	HDL	hs-CRP	APO A	APO B	SBG	HBA	PTH	FA C12:0	FA C14:0	FA C16:0	FA C16:1 n-7	FA C18:0	FA C18:1 n-7	FA C18:1 n-9	FA C18:1 n-11	FA C18:1 n-13	FA C18:2 n-6	FA C18:2 n-7	FA C18:2 n-8	FA C18:2 n-9	FA C18:2 n-10	FA C18:2 n-11	FA C18:2 n-12	FA C18:2 n-13	FA C18:2 n-14	FA C18:2 n-15	FA C18:2 n-16	FA C18:2 n-17	FA C18:2 n-18	FA C18:2 n-19	FA C18:2 n-20	FA C18:2 n-21	FA C18:2 n-22	FA C18:2 n-23	FA C18:2 n-24	FA C18:2 n-25	FA C18:2 n-26	FA C18:2 n-27	FA C18:2 n-28	FA C18:2 n-29	FA C18:2 n-30	FA C18:2 n-31	FA C18:2 n-32	FA C18:2 n-33	FA C18:2 n-34	FA C18:2 n-35	FA C18:2 n-36	FA C18:2 n-37	FA C18:2 n-38	FA C18:2 n-39	FA C18:2 n-40	FA C18:2 n-41	FA C18:2 n-42	FA C18:2 n-43	FA C18:2 n-44	FA C18:2 n-45	FA C18:2 n-46	FA C18:2 n-47	FA C18:2 n-48	FA C18:2 n-49	FA C18:2 n-50	FA C18:2 n-51	FA C18:2 n-52	FA C18:2 n-53	FA C18:2 n-54	FA C18:2 n-55	FA C18:2 n-56	FA C18:2 n-57	FA C18:2 n-58	FA C18:2 n-59	FA C18:2 n-60	FA C18:2 n-61	FA C18:2 n-62	FA C18:2 n-63	FA C18:2 n-64	FA C18:2 n-65	FA C18:2 n-66	FA C18:2 n-67	FA C18:2 n-68	FA C18:2 n-69	FA C18:2 n-70	FA C18:2 n-71	FA C18:2 n-72	FA C18:2 n-73	FA C18:2 n-74	FA C18:2 n-75	FA C18:2 n-76	FA C18:2 n-77	FA C18:2 n-78	FA C18:2 n-79	FA C18:2 n-80	FA C18:2 n-81	FA C18:2 n-82	FA C18:2 n-83	FA C18:2 n-84	FA C18:2 n-85	FA C18:2 n-86	FA C18:2 n-87	FA C18:2 n-88	FA C18:2 n-89	FA C18:2 n-90	FA C18:2 n-91	FA C18:2 n-92	FA C18:2 n-93	FA C18:2 n-94	FA C18:2 n-95	FA C18:2 n-96	FA C18:2 n-97	FA C18:2 n-98	FA C18:2 n-99	FA C18:2 n-100	FA C18:2 n-101	FA C18:2 n-102	FA C18:2 n-103	FA C18:2 n-104	FA C18:2 n-105	FA C18:2 n-106	FA C18:2 n-107	FA C18:2 n-108	FA C18:2 n-109	FA C18:2 n-110	FA C18:2 n-111	FA C18:2 n-112	FA C18:2 n-113	FA C18:2 n-114	FA C18:2 n-115	FA C18:2 n-116	FA C18:2 n-117	FA C18:2 n-118	FA C18:2 n-119	FA C18:2 n-120	FA C18:2 n-121	FA C18:2 n-122	FA C18:2 n-123	FA C18:2 n-124	FA C18:2 n-125	FA C18:2 n-126	FA C18:2 n-127	FA C18:2 n-128	FA C18:2 n-129	FA C18:2 n-130	FA C18:2 n-131	FA C18:2 n-132	FA C18:2 n-133	FA C18:2 n-134	FA C18:2 n-135	FA C18:2 n-136	FA C18:2 n-137	FA C18:2 n-138	FA C18:2 n-139	FA C18:2 n-140	FA C18:2 n-141	FA C18:2 n-142	FA C18:2 n-143	FA C18:2 n-144	FA C18:2 n-145	FA C18:2 n-146	FA C18:2 n-147	FA C18:2 n-148	FA C18:2 n-149	FA C18:2 n-150	FA C18:2 n-151	FA C18:2 n-152	FA C18:2 n-153	FA C18:2 n-154	FA C18:2 n-155	FA C18:2 n-156	FA C18:2 n-157	FA C18:2 n-158	FA C18:2 n-159	FA C18:2 n-160	FA C18:2 n-161	FA C18:2 n-162	FA C18:2 n-163	FA C18:2 n-164	FA C18:2 n-165	FA C18:2 n-166	FA C18:2 n-167	FA C18:2 n-168	FA C18:2 n-169	FA C18:2 n-170	FA C18:2 n-171	FA C18:2 n-172	FA C18:2 n-173	FA C18:2 n-174	FA C18:2 n-175	FA C18:2 n-176	FA C18:2 n-177	FA C18:2 n-178	FA C18:2 n-179	FA C18:2 n-180	FA C18:2 n-181	FA C18:2 n-182	FA C18:2 n-183	FA C18:2 n-184	FA C18:2 n-185	FA C18:2 n-186	FA C18:2 n-187	FA C18:2 n-188	FA C18:2 n-189	FA C18:2 n-190	FA C18:2 n-191	FA C18:2 n-192	FA C18:2 n-193	FA C18:2 n-194	FA C18:2 n-195	FA C18:2 n-196	FA C18:2 n-197	FA C18:2 n-198	FA C18:2 n-199	FA C18:2 n-200	FA C18:2 n-201	FA C18:2 n-202	FA C18:2 n-203	FA C18:2 n-204	FA C18:2 n-205	FA C18:2 n-206	FA C18:2 n-207	FA C18:2 n-208	FA C18:2 n-209	FA C18:2 n-210	FA C18:2 n-211	FA C18:2 n-212	FA C18:2 n-213	FA C18:2 n-214	FA C18:2 n-215	FA C18:2 n-216	FA C18:2 n-217	FA C18:2 n-218	FA C18:2 n-219	FA C18:2 n-220	FA C18:2 n-221	FA C18:2 n-222	FA C18:2 n-223	FA C18:2 n-224	FA C18:2 n-225	FA C18:2 n-226	FA C18:2 n-227	FA C18:2 n-228	FA C18:2 n-229	FA C18:2 n-230	FA C18:2 n-231	FA C18:2 n-232	FA C18:2 n-233	FA C18:2 n-234	FA C18:2 n-235	FA C18:2 n-236	FA C18:2 n-237	FA C18:2 n-238	FA C18:2 n-239	FA C18:2 n-240	FA C18:2 n-241	FA C18:2 n-242	FA C18:2 n-243	FA C18:2 n-244	FA C18:2 n-245	FA C18:2 n-246	FA C18:2 n-247	FA C18:2 n-248	FA C18:2 n-249	FA C18:2 n-250	FA C18:2 n-251	FA C18:2 n-252	FA C18:2 n-253	FA C18:2 n-254	FA C18:2 n-255	FA C18:2 n-256	FA C18:2 n-257	FA C18:2 n-258	FA C18:2 n-259	FA C18:2 n-260	FA C18:2 n-261	FA C18:2 n-262	FA C18:2 n-263	FA C18:2 n-264	FA C18:2 n-265	FA C18:2 n-266	FA C18:2 n-267	FA C18:2 n-268	FA C18:2 n-269	FA C18:2 n-270	FA C18:2 n-271	FA C18:2 n-272	FA C18:2 n-273	FA C18:2 n-274	FA C18:2 n-275	FA C18:2 n-276	FA C18:2 n-277	FA C18:2 n-278	FA C18:2 n-279	FA C18:2 n-280	FA C18:2 n-281	FA C18:2 n-282	FA C18:2 n-283	FA C18:2 n-284	FA C18:2 n-285	FA C18:2 n-286	FA C18:2 n-287	FA C18:2 n-288	FA C18:2 n-289	FA C18:2 n-290	FA C18:2 n-291	FA C18:2 n-292	FA C18:2 n-293	FA C18:2 n-294	FA C18:2 n-295	FA C18:2 n-296	FA C18:2 n-297	FA C18:2 n-298	FA C18:2 n-299	FA C18:2 n-300	FA C18:2 n-301	FA C18:2 n-302	FA C18:2 n-303	FA C18:2 n-304	FA C18:2 n-305	FA C18:2 n-306	FA C18:2 n-307	FA C18:2 n-308	FA C18:2 n-309	FA C18:2 n-310	FA C18:2 n-311	FA C18:2 n-312	FA C18:2 n-313	FA C18:2 n-314	FA C18:2 n-315	FA C18:2 n-316	FA C18:2 n-317	FA C18:2 n-318	FA C18:2 n-319	FA C18:2 n-320	FA C18:2 n-321	FA C18:2 n-322	FA C18:2 n-323	FA C18:2 n-324	FA C18:2 n-325	FA C18:2 n-326	FA C18:2 n-327	FA C18:2 n-328	FA C18:2 n-329	FA C18:2 n-330	FA C18:2 n-331	FA C18:2 n-332	FA C18:2 n-333	FA C18:2 n-334	FA C18:2 n-335	FA C18:2 n-336	FA C18:2 n-337	FA C18:2 n-338	FA C18:2 n-339	FA C18:2 n-340	FA C18:2 n-341	FA C18:2 n-342	FA C18:2 n-343	FA C18:2 n-344	FA C18:2 n-345	FA C18:2 n-346	FA C18:2 n-347	FA C18:2 n-348	FA C18:2 n-349	FA C18:2 n-350	FA C18:2 n-351	FA C18:2 n-352	FA C18:2 n-353	FA C18:2 n-354	FA C18:2 n-355	FA C18:2 n-356	FA C18:2 n-357	FA C18:2 n-358	FA C18:2 n-359	FA C18:2 n-360	FA C18:2 n-361	FA C18:2 n-362	FA C18:2 n-363	FA C18:2 n-364	FA C18:2 n-365	FA C18:2 n-366	FA C18:2 n-367	FA C18:2 n-368	FA C18:2 n-369	FA C18:2 n-370	FA C18:2 n-371	FA C18:2 n-372	FA C18:2 n-373	FA C18:2 n-374	FA C18:2 n-375	FA C18:2 n-376	FA C18:2 n-377	FA C18:2 n-378	FA C18:2 n-379	FA C18:2 n-380	FA C18:2 n-381	FA C18:2 n-382	FA C18:2 n-383	FA C18:2 n-384	FA C18:2 n-385	FA C18:2 n-386	FA C18:2 n-387	FA C18:2 n-388	FA C18:2 n-389	FA C18:2 n-390	FA C18:2 n-391	FA C18:2 n-392	FA C18:2 n-393	FA C18:2 n-394	FA C18:2 n-395	FA C18:2 n-396	FA C18:2 n-397	FA C18:2 n-398	FA C18:2 n-399	FA C18:2 n-400	FA C18:2 n-401	FA C18:2 n-402	FA C18:2 n-403	FA C18:2 n-404	FA C18:2 n-405	FA C18:2 n-406	FA C18:2 n-407	FA C18:2 n-408	FA C18:2 n-409	FA C18:2 n-410	FA C18:2 n-411	FA C18:2 n-412	FA C18:2 n-413	FA C18:2 n-414	FA C18:2 n-415	FA C18:2 n-416	FA C18:2 n-417	FA C18:2 n-418	FA C18:2 n-419	FA C18:2 n-420	FA C18:2 n-421	FA C18:2 n-422	FA C18:2 n-423	FA C18:2 n-424	FA C18:2 n-425	FA C18:2 n-426	FA C18:2 n-427	FA C18:2 n-428	FA C18:2 n-429	FA C18:2 n-430	FA C18:2 n-431	FA C18:2 n-432	FA C18:2 n-433	FA C18:2 n-434	FA C18:2 n-435	FA C18:2 n-436	FA C18:2 n-437	FA C18:2 n-438	FA C18:2 n-439	FA C18:2 n-440	FA C18:2 n-441	FA C18:2 n-442	FA C18:2 n-443	FA C18:2 n-444	FA C18:2 n-445	FA C18:2 n-446	FA C18:2 n-447	FA C18:2 n-448	FA C18:2 n-449	FA C18:2 n-450	FA C18:2 n-451	FA C18:2 n-452	FA C18:2 n-453	FA C18:2 n-454	FA C18:2 n-455	FA C18:2 n-456	FA C18:2 n-457	FA C18:2 n-458	FA C18:2 n-459	FA C18:2 n-460	FA C18:2 n-461	FA C18:2 n-462	FA C18:2 n-463	FA C18:2 n-464	FA C18:2 n-465	FA C18:2 n-466	FA C18:2 n-467	FA C18:2 n-468	FA C18:2 n-469	FA C18:2 n-470	FA C18:2 n-471	FA C18:2 n-472	FA C18:2 n-473	FA C18:2 n-474	FA C18:2 n-475	FA C18:2 n-476	FA C18:2 n-477	FA C18:2 n-478	FA C18:2 n-479	FA C18:2 n-480	FA C18:2 n-481	FA C18:2 n-482	FA C18:2 n-483	FA C18:2 n-484	FA C18:2 n-485	FA C18:2 n-486	FA C18:2 n-487	FA C18:2 n-488	FA C18:2 n-489	FA C18:2 n-490	FA C18:2 n-491	FA C18:2 n-492	FA C18:2 n-493	FA C18:2 n-494	FA C18:2 n-495	FA C18:2 n-496	FA C18:2 n-497	FA C18:2 n-498	FA C18:2 n-499	FA C18:2 n-500	FA C18:2 n-501	FA C18:2 n-502	FA C18:2 n-503	FA C18:2 n-504	FA C18:2 n-505	FA C18:2 n-506	FA C18:2 n-507	FA C18:2 n-508	FA C18:2 n-509	FA C18:2 n-510	FA C18:2 n-511	FA C18:2 n-512	FA C18:2 n-513	FA C18:2 n-514	FA C18:2 n-515	FA C18:2 n-516	FA C18:2 n-517	FA C18:2 n-518	FA C18:2 n-519	FA C18:2 n-520	FA C18:2 n-521	FA C18:2 n-522	FA C18:2 n-523	FA C18:2 n-524	FA C18:2 n-525	FA C18:2 n-526	FA C18:2 n-527	FA C18:2 n-528	FA C18:2 n-529	FA C18:2 n-530	FA C18:2 n-531	FA C18:2 n-532	FA C18:2 n-533	FA C18:2 n-534	FA C18:2 n-535	FA C18:2 n-536	FA C18:2 n-537	FA C18:2 n-538	FA C18:2 n-539	FA C18:2 n-540	FA C18:2 n-541	FA C18:2 n-542	FA C18:2 n-543	FA C18:2 n-544	FA C18:2 n-545	FA C18:2 n-546	FA C18:2 n-547	FA C18:2 n-548	FA C18:2 n-549	FA C18:2 n-550	FA C18:2 n-551	FA C18:2 n-552	FA C18:2 n-553	FA C18:2 n-554	FA C18:2 n-555	FA C18:2 n-556	FA C18:2 n-557	FA C18:2 n-558	FA C18:2 n-559	FA C18:2 n-560	FA C18:2 n-561	FA C18:2 n-562	FA C18:2 n-563	FA C18:2 n-564	FA C18:2 n-565	FA C18:2 n-566	FA C18:2 n-567	FA C18:2 n-568	FA C18:2 n-569	FA C18:2 n-570	FA C18:2 n-571	FA C18:2 n-572	FA C18:2 n-573	FA C18:2 n-574	FA C18:2 n-575	FA C18:2 n-576	FA C18:2 n-577	FA C18:2 n-578	FA C18:2 n-579	FA C18:2 n-580	FA C18:2 n-581	FA C18:2 n-582	FA C18:2 n-583	FA C18:2 n-584	FA C18:2 n-585	FA C18:2 n-586	FA C18:2 n-587	FA C18:2 n-588	FA C18:2 n-589	FA C18:2 n-590	FA C18:2 n-591	FA C18:2 n-592	FA C18:2 n-593	FA C18:2 n-594	FA C18:2 n-595	FA C18:2 n-596	FA C18:2 n-597	FA C18:2 n-598	FA C18:2 n-599	FA C18:2 n-600	FA C18:2 n-601	FA C18:2 n-602	FA C18:2 n-603	FA C18:2 n-604	FA C18:2 n-605	FA C18:2 n-606	FA C18:2 n-607	FA C18:2 n-608	FA C18:2 n-609	FA C18:2 n-610	FA C18:2 n-611	FA C18:2 n-612	FA C18:2 n-613	FA C18:2 n-614	FA C18:2 n-615	FA C18:2 n-616	FA C18:2 n-617	FA C18:2 n-618	FA C18:2 n-619	FA C18:2 n-620	FA C18:2 n-621	FA C18:2 n-622	FA C18:2 n-623	FA C18:2 n-624	FA C18:2 n-625	FA C18:2 n-626	FA C18:2 n-627	FA C18:2 n-628	FA C18:2 n-629	FA C18:2 n-630	FA C18:2 n-631	FA C18:2 n-632	FA C18:2 n-633	FA C18:2 n-634	FA C18:2 n-635	FA C18:2 n-636	FA C18:2 n-637	FA C18:2 n-638	FA C18:2 n-639	FA C18:2 n-640	FA C18:2 n-641	FA C18:2 n-642	FA C18:2 n-643	FA C18:2 n-644	FA C18:2 n-645	FA C18:2 n-646	FA C18:2 n-647	FA C18:2 n-648	FA C18:2 n-649	FA C18:2 n-650	FA C18:2 n-651	FA C18:2 n-652	FA C18:2 n-653	FA C18:2 n-654	FA C18:2 n-655	FA C18:2 n-656	FA C18:2 n-657	FA C18:2 n-658	FA C18:2 n-659	FA C18:2 n-660	FA C18:2 n-661	FA C18:2 n-662	FA C18:2 n-663	FA C18:2 n-664	FA C18:2 n-665	FA C18:2 n-666	FA C18:2 n-667	FA C18:2 n-668	FA C18:2 n-669	FA C18:2 n-670	FA C18:2 n-671	FA C18:2 n-672	FA C18:2 n-673	FA C18:2 n-674	FA C18:2 n-675	FA C18:2 n-676	FA C18:2 n-677	FA C18:2 n-678	FA C18:2 n-679	FA C18:2 n-680	FA C18:2 n-681	FA C18:2 n-682	FA C18:2 n-683	FA C18:2 n-684	FA C18:2 n-685	FA C18:2 n-686	FA C18:2 n-687	FA C18:2 n-688	FA C18:2 n-689	FA C18:2 n-690	FA C18:2 n-691	FA C18:2 n-692	FA C18:2 n-693	FA C18:2 n-694	FA C18:2 n-695	FA C18:2 n-696	FA C18:2 n-697	FA C18:2 n-698	FA C18:2 n-699	FA C18:2 n-700	FA C18:2 n-701	FA C18:2 n-702	FA C18:2 n-703	FA C18:2 n-704	FA C18:2 n-705	FA C18:2 n-706	FA C18:2 n-707	FA C18:2 n-708	FA C18:2 n-709	FA C18:2 n-710	FA C18:2 n-711	FA C18:2 n-712	FA C18:2 n-713	FA C18:2 n-714	FA C18:2 n-715	FA C18:2 n-716	FA C18:2 n-717	FA C18:2 n-718	FA C18:2 n-719	FA C18:2 n-720	FA C18:2 n-721	FA C18:2 n-722	FA C18:2 n-723	FA C18:2 n-724	FA C18:2 n-725	FA C18:2 n-726	FA C18:2 n-727	FA C18:2 n-728	FA C18:2 n-729	FA C18:2 n-730	FA C18:2 n-731	FA C18:2 n-732	FA C18:2 n-733	FA C18:2 n-734	FA C18:2 n-735	FA C18:2 n-736	FA C18:2 n-737	FA C18:2 n-738	FA C18:2 n-739	FA C18:2 n-740	FA C18:2 n-741	FA C18:2 n-742	FA C18:2 n-743	FA C18:2 n-744	FA C18:2 n-745	FA C18:2 n-746	FA C18:2 n-747	FA C18:2 n-748	FA C18:2 n-749	FA C18:2 n-750	FA C18:2 n-751	FA C18:2 n-752	FA C18:2 n-753	FA C18:2 n-754	FA C18:2 n-755	FA C18:2 n-756	FA C18:2 n-757	FA C18:2 n-758	FA C18:2 n-759	FA C18:2 n-760	FA C18:2 n-761	FA C18:2 n-762	FA C18:2 n-763	FA C18:2 n-764	FA C18:2 n-765	FA C18:2 n-766	FA C18:2 n-767	FA C18:2 n-768	FA C18:2 n-769	FA C18:2 n-770	FA C18:2 n-771	FA C18:2 n-772
---------	-----	-----	-----	----	------------	-----	--------	-------	-------	-----	-----	-----	----------	----------	----------	--------------	----------	--------------	--------------	---------------	---------------	--------------	--------------	--------------	--------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

Table 8: Biomarkers that are statistically significant with respect the blood variables in women, after applying Bonferroni correction. Non-significant values appears as a white space for easy reading.

4.4 Social Influence

4.4.1 Bootstrapping and simulation

4.4.2 Principal component analysis

4.4.3 Friendship distance matrix

We did a selection of people in the social network. For each person who has at least 2 friends of the same sex, and using the network of same sex only, we measure the distance between people who are friends and compared against people who are not friend. We compared for significant between the differences of distance averages of each biomarker, meaning that if there is significance, your friends and your biomarkers tend to converge to a similar value, hence affecting each others.

4.5 Biomarkers and diseases

4.6 Biomarkers and medicine

5 Discussion

6 Toy section

We should delete this section eventually

This is just to test where the floating images fall in the text. Go wild and do whatever you want here.



Figure 3: A majestic grizzly bear

In hac habitasse [?] platea dictumst. [?] , Vivamus eu finibus leo. Donec malesuada dui non sagittis auctor. Aenean condimentum eros metus. Nunc tempus id velit ut tempus. Quisque fermentum, nisl sit amet consectetur ornare.

This sentence requires multiple citations to imply that it is better supported. Finally, when conducting an appeal to authority, it can be useful to cite a reference in-text, much like do quite a bit. Oh, and make sure to check out the bear in Figure 3.

$$A = \begin{bmatrix} A_{11} & A_{21} \\ A_{21} & A_{22} \end{bmatrix} \quad (1)$$

Some random text here

1. First numbered item in a list
2. Second numbered item in a list
3. Third numbered item in a list

Pellentesque ac nisi dolor. Pellentesque maximus est arcu, eu scelerisque est rutrum vitae. Mauris ullamcorper vulputate vehicula. Praesent fermentum leo ac velit accumsan consectetur. Aliquam eleifend ex eros, ut lacinia tellus volutpat non. Pellentesque sit amet cursus diam. Maecenas elementum mattis est, in tincidunt ex pretium ac. Integer ultrices nunc rutrum, pretium sapien vitae, lobortis velit.

First This is the first item

Last This is the last item

Donec nec nibh sagittis, finibus mauris quis, laoreet augue. Maecenas aliquam sem nunc, vel semper urna hendrerit nec. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Maecenas pellentesque dolor lacus, sit amet pretium felis vestibulum finibus. Duis tincidunt sapien faucibus nisi vehicula tincidunt. Donec euismod suscipit ligula a tempor. Aenean a nulla sit amet magna ullamcorper condimentum. Fusce eu velit vitae libero varius condimentum at sed dui.

Aliquam elementum nulla at arcu finibus aliquet. Praesent congue ultrices nisl pretium posuere. Nunc vel nulla hendrerit, ultrices justo ut, ultrices sapien. Duis ut arcu at nunc pellentesque consectetur. Vestibulum eget nisl porta, ultricies orci eget.

Table 9: Example table

Name		
First Name	Last Name	Grade
John	Doe	7.5
Richard	Miles	5

References

- [1] A. C. Nicholas and H. F. James, “The spread of obesity in a large social network over 32 years,” *The New England Journal of Medicine*, 2007. <https://www.nejm.org/doi/full/10.1056/NEJMsa066082>.
- [2] A. Winther, E. Dennison, L. Ahmed, A. Furberg, G. Grimnes, R. Jorde, C. Gjesdal, and N. Emaus, “Fit futures: a study of norwegian adolescents’ lifestyle and bone health,” *Arch Osteoporos* 2014;9:185, September 2014. <https://link.springer.com/article/10.1007/s11657-014-0185-0>.
- [3] O. H. AB, “Olink target 96 inflammation,” February 2022. <https://www.olink.com/products-services/target/inflammation/>.
- [4] igraph, “igraph,” February 2022. <https://igraph.org/>.
- [5] statnet, “statnet,” February 2022. <https://statnet.org/>.
- [6] ggraph, “ggraph,” February 2022. <https://ggraph.data-imaginist.com/>.

7 Supplementary material

In this section, we present some useful extra information

7.1 Biomarkers

Acronym	Protein	UniProt	LOD_Batch_20160383	LOD_Batch_20160977	UniProt_Web	Wiki_Web
ADA	Adenosine Deaminase	P00813	0.436494	1.584419	http://www.uniprot.org/uniprot/P00813	http://en.wikipedia.org/wiki/Adenosine_deaminase
ARTN	Artemin	Q5T4W7	0.031349	0.031349	http://www.uniprot.org/uniprot/Q5T4W7	http://en.wikipedia.org/wiki/Artemin
ASXN1	Asx1	015169	0.845030	0.576816	http://www.uniprot.org/uniprot/P01569	http://en.wikipedia.org/wiki/ASX1
BDNF	Brain-derived neurotrophic factor	P23560	-0.380273	-0.045445	http://www.uniprot.org/uniprot/P23560	http://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor
BNGF	Beta-nerve growth factor	P01138	0.755167	0.631771	http://www.uniprot.org/uniprot/P01138	
CASP8	Caspase-8	Q14790	0.507711	0.151261	http://www.uniprot.org/uniprot/Q14790	http://en.wikipedia.org/wiki/Caspase_8
COL11	Col1a1	P51671	1.427776	0.950032	http://www.uniprot.org/uniprot/P51671	http://en.wikipedia.org/wiki/COL11
COL19	C motif chemokine 19	Q99731	0.988040	-0.038660	http://www.uniprot.org/uniprot/Q99731	http://en.wikipedia.org/wiki/COL19
COL20	C motif chemokine 20	P78556	1.276281	1.290873	http://www.uniprot.org/uniprot/P78556	http://en.wikipedia.org/wiki/COL20
COL23	C motif chemokine 23	P55773	0.780150	0.047888	http://www.uniprot.org/uniprot/P55773	http://en.wikipedia.org/wiki/COL23
COL25	C motif chemokine 25	C15444	1.087323	0.634603	http://www.uniprot.org/uniprot/C15444	http://en.wikipedia.org/wiki/COL25
COL28	C motif chemokine 28	Q9N823	0.069990	-0.066666	http://www.uniprot.org/uniprot/Q9N823	http://en.wikipedia.org/wiki/COL28
COL3	C motif chemokine 3	P10147	-0.077074	-0.534618	http://www.uniprot.org/uniprot/P10147	http://en.wikipedia.org/wiki/COL3
COL4	C motif chemokine 4	P13236	0.390603	-0.121811	http://www.uniprot.org/uniprot/P13236	http://en.wikipedia.org/wiki/COL4
CD244	Natural killer cell receptor 284	Q982W8	1.658169	1.062742	http://www.uniprot.org/uniprot/Q982W8	http://en.wikipedia.org/wiki/CD244
CD40	CD40L receptor	P25942	0.757131	-0.447591	http://www.uniprot.org/uniprot/P25942	http://en.wikipedia.org/wiki/CD40L_receptor
CD5	T cell surface glycoprotein CD5	P06127	-0.487334	-0.578852	http://www.uniprot.org/uniprot/P06127	http://en.wikipedia.org/wiki/CD5_(protein)
CD6	T cell surface glycoprotein CD6 isoform	Q8WU07	-0.194972	-0.146330	http://www.uniprot.org/uniprot/Q8WU07	http://en.wikipedia.org/wiki/CD6
CDP1	CU1 domain-containing protein 1	Q9H5V8	0.367527	0.038621	http://www.uniprot.org/uniprot/Q9H5V8	http://en.wikipedia.org/wiki/CDP1
CSF1	Macrophage colony-stimulating factor 1	P09603	-0.003590	0.396328	http://www.uniprot.org/uniprot/P09603	http://en.wikipedia.org/wiki/Colony-stimulating_factor_1
CSY5	Cystatin D	P28325	0.046105	5.808007	http://www.uniprot.org/uniprot/P28325	http://en.wikipedia.org/wiki/CSY5
CXCL1	Fractalkine	P78423	1.875148	1.166002	http://www.uniprot.org/uniprot/P78423	http://en.wikipedia.org/wiki/CXCL1
CXCL10	C motif chemokine 10	P09341	1.387787	0.758507	http://www.uniprot.org/uniprot/P09341	http://en.wikipedia.org/wiki/CXCL10
CXCL11	C motif chemokine 11	P02778	1.534295	1.358654	http://www.uniprot.org/uniprot/P02778	http://en.wikipedia.org/wiki/CXCL11
CXCL5	C motif chemokine 5	Q14625	1.471448	0.111323	http://www.uniprot.org/uniprot/Q14625	http://en.wikipedia.org/wiki/CXCL5
CXCL6	C motif chemokine 6	P42830	1.184377	1.639521	http://www.uniprot.org/uniprot/P42830	http://en.wikipedia.org/wiki/CXCL6
CXCL9	C motif chemokine 9	P80162	0.843005	0.396862	http://www.uniprot.org/uniprot/P80162	http://en.wikipedia.org/wiki/CXCL9
DNFR	Delta and Notch-like epidermal growth factor-related receptor	Q8NFT8	-0.127219	-0.730436	http://www.uniprot.org/uniprot/Q8NFT8	http://en.wikipedia.org/wiki/DNFR
EIF4BIP1	Eukaryotic translation initiation factor 4E-binding protein 1	Q13541	0.893928	0.969980	http://www.uniprot.org/uniprot/Q13541	http://en.wikipedia.org/wiki/EIF4BIP1
ENRAGE	Protein S100-A12	P80511	0.313350	0.996331	http://www.uniprot.org/uniprot/P80511	http://en.wikipedia.org/wiki/S100A12
FGF19	Fibroblast growth factor 19	Q95750	0.662450	0.255022	http://www.uniprot.org/uniprot/Q95750	http://en.wikipedia.org/wiki/FGF19
FGF21	Fibroblast growth factor 21	Q9NSA1	0.844435	-0.310457	http://www.uniprot.org/uniprot/Q9NSA1	http://en.wikipedia.org/wiki/FGF21
FGF23	Fibroblast growth factor 23	Q9GZV9	1.039348	1.108382	http://www.uniprot.org/uniprot/Q9GZV9	http://en.wikipedia.org/wiki/FGF23
FGF5	Fibroblast growth factor 5	Q8N990	1.142597	0.876939	http://www.uniprot.org/uniprot/Q8N990	http://en.wikipedia.org/wiki/FGF5
FTL3L	Fms-related tyrosine kinase 3 ligand	P49771	1.866726	1.119030	http://www.uniprot.org/uniprot/P49771	http://en.wikipedia.org/wiki/FTL3L
GDNF	Glia cell line-derived neurotrophic factor	P99905	1.331378	1.648532	http://www.uniprot.org/uniprot/P99905	http://en.wikipedia.org/wiki/Glia_cell_line-derived_neurotrophic_factor
HGF	Hepatocyte growth factor	P14210	1.146276	0.839516	http://www.uniprot.org/uniprot/P14210	http://en.wikipedia.org/wiki/Hepatocyte_growth_factor
IPNG	Interferon gamma	P01579	0.992313	0.992313	http://www.uniprot.org/uniprot/P01579	http://en.wikipedia.org/wiki/Interferon_gamma
IL10	Interleukin-10	P22301	1.839415	2.452488	http://www.uniprot.org/uniprot/P22301	http://en.wikipedia.org/wiki/Interleukin_10
IL10RA	Interleukin-10 receptor subunit alpha	Q13651	0.996689	0.622247	http://www.uniprot.org/uniprot/Q13651	http://en.wikipedia.org/wiki/Interleukin_10_receptor_subunit_alpha
IL10RB	Interleukin-10 receptor subunit beta	Q08334	1.425411	1.405083	http://www.uniprot.org/uniprot/Q08334	http://en.wikipedia.org/wiki/Interleukin_10_receptor_subunit_beta
IL12B	Interleukin-12 subunit beta	P29460	-0.338237	-0.143724	http://www.uniprot.org/uniprot/P29460	http://en.wikipedia.org/wiki/Interleukin_12_receptor_subunit_beta
IL13	Interleukin-13	P53225	1.537823	1.537823	http://www.uniprot.org/uniprot/P53225	http://en.wikipedia.org/wiki/Interleukin_13
IL15RA	Interleukin-15 receptor subunit alpha	Q13261	0.783341	0.595480	http://www.uniprot.org/uniprot/Q13261	http://en.wikipedia.org/wiki/Interleukin_15_receptor_subunit_alpha
IL17A	Interleukin-17A	Q16552	0.532945	0.371852	http://www.uniprot.org/uniprot/Q16552	http://en.wikipedia.org/wiki/IL17A
IL17C	Interleukin-17C	Q9P0M4	1.371362	1.358013	http://www.uniprot.org/uniprot/Q9P0M4	
IL18	Interleukin-18	Q14116	-0.188372	0.365590	http://www.uniprot.org/uniprot/Q14116	http://en.wikipedia.org/wiki/Interleukin_18
IL18R1	Interleukin-18 receptor 1	Q13478	0.933131	0.638867	http://www.uniprot.org/uniprot/Q13478	http://en.wikipedia.org/wiki/Interleukin-18_receptor
IL1A	Interleukin-1 alpha	P01363	0.339995	1.802489	http://www.uniprot.org/uniprot/P01363	http://en.wikipedia.org/wiki/IL1A
IL2	Interleukin-2	P06568	1.222327	1.222327	http://www.uniprot.org/uniprot/P06568	http://en.wikipedia.org/wiki/Interleukin_2
IL20	Interleukin-20	Q9NYV1	0.728574	0.813528	http://www.uniprot.org/uniprot/Q9NYV1	http://en.wikipedia.org/wiki/Interleukin_20
IL20RA	Interleukin-20 receptor subunit alpha	Q9LHF4	0.877718	0.881812	http://www.uniprot.org/uniprot/Q9LHF4	
IL22RA1	Interleukin-22 receptor subunit alpha-1	Q8N697	2.260242	2.260242	http://www.uniprot.org/uniprot/Q8N697	
IL24	Interleukin-24	Q13007	1.336190	1.336190	http://www.uniprot.org/uniprot/Q13007	http://en.wikipedia.org/wiki/Interleukin_24
IL2RB	Interleukin-2 receptor subunit beta	P14784	0.845790	0.845790	http://www.uniprot.org/uniprot/P14784	http://en.wikipedia.org/wiki/IL2RB
IL33	Interleukin-33	Q95760	1.425509	1.425509	http://www.uniprot.org/uniprot/Q95760	http://en.wikipedia.org/wiki/Interleukin_33
IL4	Interleukin-4	P05112	1.184842	0.958605	http://www.uniprot.org/uniprot/P05112	http://en.wikipedia.org/wiki/Interleukin_4
IL5	Interleukin-5	P05113	1.725314	1.647055	http://www.uniprot.org/uniprot/P05113	http://en.wikipedia.org/wiki/Interleukin_5
IL6	Interleukin-6	P05231	0.824445	2.415735	http://www.uniprot.org/uniprot/P05231	http://en.wikipedia.org/wiki/Interleukin_6
IL7	Interleukin-7	P13232	1.021735	1.336047	http://www.uniprot.org/uniprot/P13232	http://en.wikipedia.org/wiki/Interleukin_7
IL8	Interleukin-8	P10145	1.162271	2.227435	http://www.uniprot.org/uniprot/P10145	http://en.wikipedia.org/wiki/Interleukin_8
ILF3	Leukemia inhibitory factor	P15018	0.808844	0.808844	http://www.uniprot.org/uniprot/P15018	http://en.wikipedia.org/wiki/Leukemia_inhibitory_factor
ILF8	Leukemia inhibitory factor receptor	P42762	1.665534	-0.265929	http://www.uniprot.org/uniprot/P42762	http://en.wikipedia.org/wiki/ILF8
MCPI	Monocyte chemoattractant protein 1	P13500	0.358877	-0.161967	http://www.uniprot.org/uniprot/P13500	http://en.wikipedia.org/wiki/Monocyte_chemoattractant_protein_1
MCPI2	Monocyte chemoattractant protein 2	P80075	1.385177	1.823898	http://www.uniprot.org/uniprot/P80075	
MCPI3	Monocyte chemoattractant protein 3	P80098	1.493173	1.699734	http://www.uniprot.org/uniprot/P80098	
MCPI4	Monocyte chemoattractant protein 4	Q99616	-0.265469	-0.298464	http://www.uniprot.org/uniprot/Q99616	
MMP1	Matrix metalloproteinase-1	P03956	-0.024189	-6.622735	http://www.uniprot.org/uniprot/P03956	http://en.wikipedia.org/wiki/Matrix_metalloproteinase
MMP10	Matrix metalloproteinase-10	P09238	1.379258	3.725904	http://www.uniprot.org/uniprot/P09238	http://en.wikipedia.org/wiki/MMP10
NRTN	Neurturin	Q99748	1.124936	1.124936	http://www.uniprot.org/uniprot/Q99748	http://en.wikipedia.org/wiki/Neurturin
NT3	Neurotrophin-3	P20783	0.771270	0.918843	http://www.uniprot.org/uniprot/P20783	http://en.wikipedia.org/wiki/Neurotrophin-3
OPG	Osteoprotegerin	Q00300	0.918419	0.590118	http://www.uniprot.org/uniprot/Q00300	http://en.wikipedia.org/wiki/Osteoprotegerin
OSM	Oncostatin-M	P13725	-0.153103	-0.025163	http://www.uniprot.org/uniprot/P13725	http://en.wikipedia.org/wiki/Oncostatin_M
PDL1	Programmed cell death 1 ligand 1	Q9NC07	2.257993	2.092503	http://www.uniprot.org/uniprot/Q9NC07	http://en.wikipedia.org/wiki/PDL1
SCF	Shem cell factor	P21363	0.922578	0.051798	http://www.uniprot.org/uniprot/P21363	http://en.wikipedia.org/wiki/SCF
SIRT2	SIRT2-like protein 2	Q8U36	1.400289	1.386472	http://www.uniprot.org/uniprot/Q8U36	http://en.wikipedia.org/wiki/SIRT2-like_protein_2
SLAMF1	Signaling lymphocytic activation molecule	Q12391	1.849931	1.677337	http://www.uniprot.org/uniprot/Q12391	http://en.wikipedia.org/wiki/Signaling_lymphocytic_activation_molecule
STI1A1	Sulfatransferase 1A1	P50225	0.078597	0.568043	http://www.uniprot.org/uniprot/P50225	http://en.wikipedia.org/wiki/STI1A1
STAMPB	STAM-binding protein	Q95630	0.667136	0.627816	http://www.uniprot.org/uniprot/Q95630	http://en.wikipedia.org/wiki/STAMPB
TGFA	Transforming growth factor alpha	P01135	-1.214780	-1.869967	http://www.uniprot.org/uniprot/P01135	http://en.wikipedia.org/wiki/TGF_alpha
TGFB1	Latency-associated peptide transforming growth factor-beta-1	P01137	1.034369	0.482168	http://www.uniprot.org/uniprot/P01137	http://en.wikipedia.org/wiki/TGF_beta_1
TNF	Tumor necrosis factor	P01375	0.831649	0.837656	http://www.uniprot.org/uniprot/P01375	http://en.wikipedia.org/wiki/Tumor_necrosis_factor
TNFB	TNF-beta	P01374	0.605630	0.200990	http://www.uniprot.org/uniprot/P01374	http://en.wikipedia.org/wiki/TNF_beta
TNFRSF9	Tumor necrosis factor receptor superfamily member 9	Q07011	1.599546	1.466786	http://www.uniprot.org/uniprot/Q07011	http://en.wikipedia.org/wiki/TNFRSF9
TNFRSF14	Tumor necrosis factor ligand superfamily member 14	Q43557	0.210933	-0.170624	http://www.uniprot.org/uniprot/Q43557	http://en.wikipedia.org/wiki/TNFRSF14
TRAIL	TNF-related apoptosis-inducing ligand	P50591	0.651508	0.548601	http://www.uniprot.org/uniprot/P50591	http://en.wikipedia.org/wiki/TRAIL
TRANCE	TNF-related activation-induced cytokine	Q14788	1.283670	1.118725	http://www.uniprot.org/uniprot/Q14788	http://en.wikipedia.org/wiki/TNF-related_activation-induced_cytokine
TSIP	Thymic stromal lymphopoietin	Q96079	1.080835	1.080835	http://www.uniprot.org/uniprot/Q96079	

Acronym	Protein	Significance	Men	Women
ADA	Adenosine Deaminase	****	5.16	4.75
ARTN	Artemin	ns	-0.21	-0.22
AXIN1	Axin-1	****	1.19	1.07
BDNF	Brain-derived neurotrophic factor	***	4.61	3.76
BNGF	Beta-nerve growth factor	ns	1.93	1.93
CASP8	Caspase-8	*	1.46	1.4
CCL11	Eotaxin	****	7.9	7.76
CCL19	C-C motif chemokine 19	ns	9.37	9.37
CCL20	C-C motif chemokine 20	ns	6.06	6.06
CCL23	C-C motif chemokine 23	ns	9.35	9.39
CCL25	C-C motif chemokine 25	**	6.17	6.05
CCL28	C-C motif chemokine 28	****	0.83	1.26
CCL3	C-C motif chemokine 3	ns	2.24	2.2
CCL4	C-C motif chemokine 4	****	6.58	6.44
CD244	Natural killer cell receptor 2B4	***	6.38	6.31
CD40	CD40L receptor	****	9.29	9.18
CD5	T-cell surface glycoprotein CD5	**	4.05	3.99
CD6	T cell surface glycoprotein CD6 isoform	ns	3.65	3.59
CDCP1	CUB domain-containing protein 1	ns	2.44	2.41
CSF1	Macrophage colony-stimulating factor 1	*	7.87	7.9
CST5	Cystatin D	****	6.87	6.75
CX3CL1	Fractalkine	ns	6.52	6.52
CXCL1	C-X-C motif chemokine 1	****	8.72	8.85
CXCL10	C-X-C motif chemokine 10	ns	9.51	9.6
CXCL11	C-X-C motif chemokine 11	**	7.1	7.24
CXCL5	C-X-C motif chemokine 5	****	12.1	12.53
CXCL6	C-X-C motif chemokine 6	ns	9.08	9.02
CXCL9	C-X-C motif chemokine 9	ns	7.29	7.28
DNER	Delta and Notch-like epidermal growth factor-related receptor	****	7.35	7.27
EIF4EBP1	Eukaryotic translation initiation factor 4E-binding protein 1	****	5.99	5.5
ENRAGE	Protein S100-A12	ns	5.16	5.11
FGF19	Fibroblast growth factor 19	ns	7.88	7.87
FGF21	Fibroblast growth factor 21	ns	3.16	3.13
FGF23	Fibroblast growth factor 23	ns	2.68	2.63
FGF5	Fibroblast growth factor 5	ns	1.42	1.43
FLT3L	Fms-related tyrosine kinase 3 ligand	*	8.78	8.83
GDNF	Glial cell line-derived neurotrophic factor	***	2.17	2.08
HGF	Hepatocyte growth factor	****	7.8	7.91
IFNG	Interferon gamma	ns	0.62	0.63
IL10	Interleukin-10	ns	4.14	4.11
IL10RA	Interleukin-10 receptor subunit alpha	ns	1.41	1.37
IL10RB	Interleukin-10 receptor subunit beta	****	7.61	7.47
IL12B	Interleukin-12 subunit beta	ns	4.81	4.85
IL13	Interleukin-13	ns	1.06	1.02
IL15RA	Interleukin-15 receptor subunit alpha	****	1.31	1.22
IL17A	Interleukin-17A	ns	0.83	0.8
IL17C	Interleukin-17C	****	1.72	1.58
IL18	Interleukin-18	ns	7.07	7.02
IL18R1	Interleukin-18 receptor 1	**	7.61	7.53
IL1A	Interleukin-1 alpha	***	1.04	1.18
IL2	Interleukin-2	ns	0.74	0.74
IL20	Interleukin-20	ns	0.54	0.52
IL20RA	Interleukin-20 receptor subunit alpha	ns	0.75	0.73
IL22RA1	Interleukin-22 receptor subunit alpha-1	ns	0.33	0.3
IL24	Interleukin-24	ns	0.73	0.72
IL2RB	Interleukin-2 receptor subunit beta	ns	0.52	0.51
IL33	Interleukin-33	ns	0.97	0.98
IL4	Interleukin-4	****	1.13	0.85
IL5	Interleukin-5	**	1.73	1.95
IL6	Interleukin-6	ns	2.85	2.84
IL7	Interleukin-7	ns	5.27	5.21
IL8	Interleukin-8	ns	7.56	7.52
ILF	Leukemia inhibitory factor	ns	0.46	0.46
ILFR	Leukemia inhibitory factor receptor	ns	3.4	3.38
MCP1	Monocyte chemoattractant protein 1	****	10.01	9.79
MCP2	Monocyte chemoattractant protein 2	ns	10.03	10.02
MCP3	Monocyte chemoattractant protein 3	ns	2.23	2.25
MCP4	Monocyte chemoattractant protein 4	ns	3.47	3.42
MMP1	Matrix metalloproteinase-1	ns	6.86	6.95
MMP10	Matrix metalloproteinase-10	**	8.83	8.95
NRTN	Neurturin	ns	0.91	0.94
NT3	Neurotrophin-3	**	2.19	2.09
OPG	Osteoprotegerin	ns	9.68	9.71
OSM	Oncostatin-M	****	4.42	4.79
PDL1	Programmed cell death 1 ligand 1	****	5.07	4.87
SCF	Stem cell factor	****	9.28	9.15
SIRT2	SIR2-like protein 2	**	3.01	2.9
SLAMF1	Signaling lymphocytic activation molecule	****	3.2	3.05
ST1A1	Sulfotransferase 1A1	ns	2.04	2
STAMBP	STAM-binding protein	****	2.74	2.58
TGFA	Transforming growth factor alpha	****	3.59	3.88
TGFB1	Latency-associated peptide transforming growth factor beta-1	****	8.1	7.99
TNF	Tumor necrosis factor	ns	0.47	0.45
TNFB	TNF-beta	ns	3.99	3.98
TNFRSF9	Tumor necrosis factor receptor superfamily member 9	****	7.19	6.68
TNFSF14	Tumor necrosis factor ligand superfamily member 14	**	4.62	4.71
TRAIL	TNF-related apoptosis-inducing ligand	****	8.39	8.18
TRANCE	TNF-related activation-induced cytokine	****	5.97	5.5
TSLP	Thymic stromal lymphopoietin	ns	0.42	0.46
TWEAK	Tumor necrosis factor	****	9.02	8.88
UPA	Urokinase-type plasminogen activator	****	10.07	9.87
VEGFA	Vascular endothelial growth factor A	ns	10.2	10.22

Table 11: Sex differences for each biomarker

Sex	Man	Woman	Total	Freq
Man	530 (0.51)	0 (0)	530	0.51
Woman	0 (0)	508 (0.49)	508	0.49
Total	530	508	1038	
Freq	0.51	0.49	1	

Table 12: Sex differences for Sex

GeneralHealth	Very bad	Bad	Neither good nor bad	Good	Excellent	Total	Freq
Man	3 (0)	23 (0.02)	110	261 (0.11)	125 (0.26)	522	0.51
Woman	4 (0)	30 (0.03)	108	236 (0.11)	116 (0.23)	494	0.49
Total	7	53	218	497	241	1018	
Freq	0.01	0.05		0.21	0.49		0.24

Table 13: Sex differences for GeneralHealth

BMICategorical	Underweight	Healthy	Overweight	Obese	Total	Freq
Man	67 (0.06)	351 (0.34)	78 (0.08)	33 (0.03)	529	0.51
Woman	43 (0.04)	359 (0.35)	69 (0.07)	34 (0.03)	505	0.49
Total	110	710	147	67	1034	
Freq	0.11	0.69	0.14	0.06		1

Table 14: Sex differences for BMICategorical

Smoke	Never	Sometimes	Daily	Total	Freq
Man	393 (0.39)	107 (0.11)	20 (0.02)	520	0.51
Woman	389 (0.38)	81 (0.08)	28 (0.03)	498	0.49
Total	782	188	48	1018	
Freq	0.77	0.18	0.05	1	

Table 15: Sex differences for Smoke

Snuff	Never	Sometimes	Daily	Total	Freq
Man	306 (0.3)	64 (0.06)	149 (0.15)	519	0.51
Woman	336 (0.33)	67 (0.07)	96 (0.09)	499	0.49
Total	642	131	245	1018	
Freq	0.63	0.13	0.24	1	

Table 16: Sex differences for Snuff

Alcohol	Never	Once per month or less	Twice of more per month	Total	Freq
Man	161 (0.16)	193 (0.19)	164 (0.16)	518	0.51
Woman	119 (0.12)	227 (0.22)	154 (0.15)	500	0.49
Total	280	420	318	1018	
Freq	0.28	0.41	0.31	1	

Table 17: Sex differences for Alcohol

SportsLeisure	None	Light	Medium	Hard	Total	Freq
Man	154 (0.15)	132 (0.13)	120 (0.12)	114 (0.11)	520	0.51
Woman	75 (0.07)	206 (0.2)	139 (0.14)	80 (0.08)	500	0.49
Total	229	338	259	194	1020	
Freq	0.22	0.33	0.25	0.19	1	

Table 18: Sex differences for SportsLeisure

SummerTransport	By car or moped		By bus		By bike		On foot		Unknown	
Man	73	(0.07)	341	(0.33)	36	(0.03)	70	(0.07)	10	(0.01)
Woman	46	(0.04)	345	(0.33)	23	(0.02)	86	(0.08)	8	(0.01)
Total	119		686		59		156		18	
Freq		0.11		0.66		0.06		0.15		0.02

Table 19: Sex differences for SummerTransport

WinterTransport	By car or moped		By bus		By bike		On foot		Unknown	
Man	44	(0.04)	388	(0.37)	6	(0.01)	69	(0.07)	23	(0.02)
Woman	38	(0.04)	384	(0.37)	5	(0)	70	(0.07)	11	(0.01)
Total	82		772		11		139		34	
Freq		0.08		0.74		0.01		0.13		0.03

Table 20: Sex differences for WinterTransport

ScreenTime	None	About half an hour		About 1 to 1,5 hours		About 2 to 3 hours		Abou
Man	0	(0)	21	(0.02)	84	(0.08)	185	(0.18)
Woman	1	(0)	21	(0.02)	90	(0.09)	201	(0.19)
Total	1		42		174		386	
Freq		0		0.04		0.17		0.37

Table 21: Sex differences for ScreenTime

LeanFishFrequency	Rarely/Never		1-3 times per month		1-3 times per week		4-6 times per week	
Man	106	(0.1)	235	(0.23)	152	(0.15)	15	
Woman	113	(0.11)	226	(0.22)	136	(0.13)	18	
Total	219		461		288		33	
Freq		0.21		0.44		0.28		

Table 22: Sex differences for LeanFishFrequency

FatFishFrequency	Rarely/Never		1-3 times per month		1-3 times per week		4-6 times per week	
Man	124	(0.12)	235	(0.23)	133	(0.13)	26	
Woman	101	(0.1)	239	(0.23)	133	(0.13)	17	
Total	225		474		266		43	
Freq		0.22		0.46		0.26		

Table 23: Sex differences for FatFishFrequency

CheeseFrequency	Rarely/Never		1-3 times per month		1-3 times per week		4-6 times per week	
Man	28	(0.03)	81	(0.08)	201	(0.19)	149	
Woman	25	(0.02)	83	(0.08)	198	(0.19)	126	
Total	53		164		399		275	
Freq		0.05		0.16		0.38		

Table 24: Sex differences for CheeseFrequency

ChocolateFrequency	Rarely/Never		1-3 times per month		1-3 times per week		4-6 times per week	
Man	35	(0.03)	120	(0.12)	294	(0.28)	56	
Woman	37	(0.04)	131	(0.13)	254	(0.24)	55	
Total	72		251		548		111	
Freq		0.07		0.24		0.53		

Table 25: Sex differences for ChocolateFrequency

FruitsFrequency	Rarely/Never	1-3 times per month	1-3 times per week	4-6 times per week
Man	19 (0.02)	61 (0.06)	161 (0.16)	122
Woman	27 (0.03)	56 (0.05)	156 (0.15)	97
Total	46	117	317	219
Freq	0.04	0.11	0.31	

Table 26: Sex differences for FruitsFrequency

VegetablesFrequency	Rarely/Never	1-3 times per month	1-3 times per week	4-6 times per w
Man	22 (0.02)	49 (0.05)	132 (0.13)	160
Woman	21 (0.02)	43 (0.04)	119 (0.11)	159
Total	43	92	251	319
Freq	0.04	0.09	0.24	

Table 27: Sex differences for VegetablesFrequency

DairyFrequency	Rarely/Never	1-6 glasses per week	1 glass per day	2-3 glasses per day
Man	269 (0.26)	200 (0.19)	30 (0.03)	18 (0.01)
Woman	269 (0.26)	173 (0.17)	28 (0.03)	21 (0.02)
Total	538	373	58	39
Freq	0.52	0.36	0.06	0.01

Table 28: Sex differences for DairyFrequency

FruitJuiceFrequency	Rarely/Never	1-6 glasses per week	1 glass per day	2-3 glasses per day
Man	90 (0.09)	227 (0.22)	120 (0.12)	67 (0.06)
Woman	73 (0.07)	257 (0.25)	91 (0.09)	68 (0.06)
Total	163	484	211	135
Freq	0.16	0.47	0.2	

Table 29: Sex differences for FruitJuiceFrequency

SugarJuiceFrequency	Rarely/Never	1-6 glasses per week	1 glass per day	2-3 glasses per day
Man	315 (0.3)	148 (0.14)	35 (0.03)	18 (0.01)
Woman	294 (0.28)	148 (0.14)	28 (0.03)	22 (0.02)
Total	609	296	63	40
Freq	0.59	0.29	0.06	

Table 30: Sex differences for SugarJuiceFrequency

SugarDrinkFrequency	Rarely/Never	1-6 glasses per week	1 glass per day	2-3 glasses per day
Man	112 (0.11)	276 (0.27)	61 (0.06)	47 (0.04)
Woman	110 (0.11)	264 (0.25)	61 (0.06)	41 (0.03)
Total	222	540	122	88
Freq	0.21	0.52	0.12	

Table 31: Sex differences for SugarDrinkFrequency

SweetenerDrinkFrequency	Rarely/Never	1-6 glasses per week	1 glass per day	2-3 glasses per
Man	286 (0.28)	182 (0.18)	27 (0.03)	11 (0.01)
Woman	282 (0.27)	154 (0.15)	36 (0.03)	13 (0.01)
Total	568	336	63	24
Freq	0.55	0.32	0.06	

Table 32: Sex differences for SweetenerDrinkFrequency




Figure 4: Overview of all antropometric variables differences with respect sex.

WaterFrequency	Rarely/Never	1-6 glasses per week		1 glass per day		2-3 glasses per day	
Man	10	(0.01)	48	(0.05)	86	(0.08)	163
Woman	8	(0.01)	30	(0.03)	78	(0.08)	174
Total	18		78		164		337
Freq		0.02		0.08		0.16	

Table 33: Sex differences for WaterFrequency

HighSchool	H1		H2		H3		H4		H5		H6		H7		H8	
Man	135	(0.13)	36	(0.03)	62	(0.06)	63	(0.06)	38	(0.04)	16	(0.02)	102	(0.1)	78	(0.08)
Woman	72	(0.07)	106	(0.1)	106	(0.1)	35	(0.03)	47	(0.05)	10	(0.01)	90	(0.09)	42	(0.07)
Total	207		142		168		98		85		26		192		120	
Freq	0.2		0.14		0.16		0.09		0.08		0.03		0.18		0.1	

Table 34: Sex differences for HighSchool

7.2 Antropometry

7.3 Host factors tables

7.4 Blood

7.5 Biomarkers significance without correction

Description	Short	Unit	Lower Limit	Upper Limit	\bar{x}_{men}	\bar{x}_{women}	Significance	Freq_Men_Out	Freq_Women_Out
Mean corpuscular hemoglobin (pg). EDTA whole blood	MCH	pg	26.08	32.3	29.25	29.12	ns	2.2%	6.2%
Mean corpuscular hemoglobin concentration (g/dL). EDTA whole blood	MCHC	g/dL	32.23	34.85	33.68	33.39	****	4.2%	7.4%
Mean corpuscular volume (fl). EDTA whole blood	MCV	fl	78.03	95.53	87.09	86.43	*	2.1%	7.2%
Fe (µmol/L). Serum	Fe	umol/L	2.09	31.69	18.47	15.18	****	3.8%	2%
Ferritin (ug/L). Serum	Ferritin	ug/L	-21.95	112.37	57.6	31.42	****	6.3%	0.7%
Transferrin (g/L). Serum	Transferritin	g/L	2.04	3.79	2.83	3.02	****	2.9%	8.6%
Total cholesterol (mmol/L). Serum	Total cholesterol	mmol/L	2.54	5.61	3.91	4.25	****	3.4%	3.6%
Triglycerides (mmol/L). Serum	Triglycerides	mmol/L	0.05	2.13	1.13	1.05	*	5.9%	3.2%
Low density lipoprotein cholesterol (mmol/L). Serum	LDL	mmol/L	1.01	3.75	2.3	2.46	***	4%	4.1%
High density lipoprotein cholesterol (mmol/L). Serum	HDL	mmol/L	0.7	1.98	1.24	1.45	****	1.9%	7.3%
Calcium (mmol/L). Serum	Calcium	mmol/L	2.15	2.48	2.34	2.29	****	5.1%	5%
High-sensitive CRP. Serum	hs-CRP		-5.11	8.15	1.49	1.55	ns	3.6%	3%
Apolipoprotein A1 (g/L). Serum	APO A	g/L	0.88	1.71	1.22	1.37	****	3.8%	7.5%
Apolipoprotein B (g/L). Serum	APO B	g/L	0.3	0.97	0.61	0.66	****	3.8%	4.1%
Serum estradiol, E2 (nmol/L)	Estradiol	nmol/L	-0.54	0.93	0.11	0.29	****	0%	2.9%
Serum progesterone (nmol/L)	Progesterone	nmol/L	-9.19	15.18	1.81	4.32	****	0%	7.2%
Serum testosterone (nmol/L)	Testosterone	nmol/L	-7.41	24.23	15.12	0.9	****	3.4%	0%
Serum dehydroepiandrosterone sulphate (µmol/L)	DHEA	umol/L	1.29	11.83	7.24	5.8	****	6.5%	1.4%
Serum sex hormone binding globuline (SHBG) (nmol/L)	SHBG	nmol/L	0	200	28.69	66.61	****	0%	0%
Serum luteinizing hormone (LH) (IU/L)	LH	IU/L	-4.88	15.17	4.22	6.18	****	0.2%	6.3%
Serum follicle-stimulating hormone (FSH) (IU/L)	Follicle-stimulating hormone	IU/L	-1.03	8.7	3.62	4.07	**	2.2%	2%
Glucose (mmol/L). Non-fasting serum	Glucose non fasting	mmol/L	70	120	5.16	4.95	***	100%	100%
Glycated haemoglobin (%). EDTA whole blood	HbA1C	%	4.65	5.93	5.29	5.29	ns	1.9%	3.5%
Haemoglobin (g/dL). EDTA whole blood	HbA	g/dL	10.98	16.36	14.59	12.65	****	1.9%	3.9%
Albumin (g/L). Serum	Albumin	g/L	40.62	50.83	46.85	44.51	****	4.2%	6.6%
25(OH)D (nmol/L). Serum	25(OH)D	nmol/L	0.42	92.88	40.13	53.89	****	2.2%	7.2%
Retinol (µmol/L). Serum	Retinol	umol/L	0.62	4.32	2.46	2.49	ns	3.2%	5.4%
Plasma Parathyroid hormone (pmol/L)	PTH	pmol/L	1.25	7.19	4.43	3.99	****	5.1%	2.3%
FA C12:0 (mcg/ml). Serum	FA C12:0	mcg/ml	-21.76	32.95	5.71	5.47	ns	1.6%	0.9%
FA C14:0 (mcg/ml). Serum	FA C14:0	mcg/ml	-10.61	72.5	30.9	30.99	ns	4.1%	4.7%
FA C15:0 (mcg/ml). Serum	FA C15:0	mcg/ml	1.07	9.86	5.45	5.48	ns	3.2%	4.5%
FA C16:0 (mcg/ml). Serum	FA C16:0	mcg/ml	191.56	960.72	564.26	589.33	*	4.9%	6.3%
FA C16:1 n-7 (mcg/ml). Serum	FA C16:1 n-7	mcg/ml	-7.29	106.81	46.61	53.26	***	3%	5.6%
FA C18:0 (mcg/ml). Serum	FA C18:0	mcg/ml	76.01	322.85	195.89	203.35	ns	4.3%	6.3%
FA C18:1 t6-11 (mcg/ml). Serum	FA C18:1 t6-11	mcg/ml	-6.12	47.68	20.95	20.59	ns	4.5%	5%
FA C18:1 c-9 (mcg/ml). Serum	FA C18:1 c-9	mcg/ml	132.36	926.21	537.94	519.67	ns	5.1%	4.3%
FA C18:1 c-11 (mcg/ml). Serum	FA C18:1 c-11	mcg/ml	11.53	63.91	36.78	38.76	*	4.1%	6.1%
FA C18:2 n-6 (mcg/ml). Serum	FA C18:2 n-6	mcg/ml	310.87	1022.44	645.65	689.97	***	3.2%	5.9%
FA C20:0 (mcg/ml). Serum	FA C20:0	mcg/ml	2.39	14.16	7.56	9.07	****	2.6%	8.3%
FA C18:3 n-6 (mcg/ml). Serum	FA C18:3 n-6	mcg/ml	-1.41	17.68	8.23	8.04	ns	4.1%	5.6%
FA C18:3 n-3 (mcg/ml). Serum	FA C18:3 n-3	mcg/ml	-3.45	38.63	17.98	17.16	ns	4.7%	2.9%
FA C20:1 n-9 (mcg/ml). Serum	FA C20:1 n-9	mcg/ml	0.03	7.2	3.63	3.6	ns	4.1%	5.2%
FA C20:2 n-6 (mcg/ml). Serum	FA C20:2 n-6	mcg/ml	1.06	8.46	4.51	5.03	****	2.2%	7.7%
FA C22:0 (mcg/ml). Serum	FA C22:0	mcg/ml	7.73	26.89	16.29	18.44	****	2%	7.9%
FA C20:3 n-6 (mcg/ml). Serum	FA C20:3 n-6	mcg/ml	9.08	65.8	36.59	38.38	ns	2.4%	5.2%
FA C20:4 n-6 (mcg/ml). Serum	FA C20:4 n-6	mcg/ml	53.09	199.38	122.54	130.34	**	3.7%	5.9%
FA C23:0 (mcg/ml). Serum	FA C23:0	mcg/ml	2.97	11.23	6.6	7.65	****	1.8%	7.7%
FA C20:5 n-3 (mcg/ml). Serum	FA C20:5 n-3	mcg/ml	-8.06	46.77	18.51	20.3	*	3.9%	4.1%
FA C24:0 (mcg/ml). Serum	FA C24:0	mcg/ml	6.8	24.82	15.25	16.43	****	2.2%	7.2%
FA C24:1 (mcg/ml). Serum	FA C24:1	mcg/ml	13.93	44.18	27.34	30.95	****	2.4%	8.1%
FA C22:5 n-3 (mcg/ml). Serum	FA C22:5 n-3	mcg/ml	4.25	21.44	13.26	12.39	**	4.9%	3.8%
FA C22:6 n-3 (mcg/ml). Serum	FA C22:6 n-3	mcg/ml	11.93	94.5	49.07	57.82	****	3%	8.1%
FA C12:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C12:0	w%	-0.5	0.89	0.2	0.19	ns	1.6%	0.7%
FA C14:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C14:0	w%	0.12	2.13	1.15	1.1	ns	5.3%	3.4%
FA C15:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C15:0	w%	0.12	0.3	0.21	0.2	**	6.1%	2.5%
FA C16:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C16:0	w%	18.57	25.28	21.88	21.97	ns	4.7%	5.2%
FA C16:1 n-7 (weight% of Fatty Acid Methyl Esters). Serum	wFA C16:1 n-7	w%	0.59	3.1	1.77	1.93	****	3.2%	5.4%
FA C18:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:0	w%	5.93	9.37	7.66	7.64	ns	3.7%	5.9%
FA C18:1 t6-11 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:1 t6-11	w%	0.03	1.5	0.79	0.74	*	6.9%	4.5%
FA C18:1 c-9 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:1 c-9	w%	14.3	25.8	20.68	19.34	****	5.5%	3.8%
FA C18:1 c-11 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:1 c-11	w%	0.96	1.93	1.44	1.46	ns	3.2%	5.9%
FA C18:2 n-6 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:2 n-6	w%	19.15	32.66	25.58	26.26	**	5.5%	4.1%
FA C20:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:0	w%	0.17	0.47	0.3	0.34	****	2.6%	10.6%
FA C18:3 n-6 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:3 n-6	w%	0.03	0.58	0.32	0.3	*	5.1%	3.8%
FA C18:3 n-3 (weight% of Fatty Acid Methyl Esters). Serum	wFA C18:3 n-3	w%	0.14	1.17	0.68	0.63	**	5.9%	3.4%
FA C20:1 n-9 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:1 n-9	w%	0.04	0.23	0.14	0.13	*	3%	4.7%
FA C20:2 n-6 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:2 n-6	w%	0.11	0.26	0.18	0.19	****	2%	6.5%
FA C22:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C22:0	w%	0.41	0.94	0.65	0.7	****	5.5%	4.5%
FA C20:3 n-6 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:3 n-6	w%	0.81	2.06	1.44	1.43	ns	5.5%	4.5%
FA C20:4 n-6 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:4 n-6	w%	2.93	6.95	4.9	4.98	ns	4.7%	3.2%
FA C23:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C23:0	w%	0.16	0.39	0.26	0.29	****	3.4%	5.2%
FA C20:5 n-3 (weight% of Fatty Acid Methyl Esters). Serum	wFA C20:5 n-3	w%	-0.32	1.84	0.74	0.78	ns	3.7%	4.1%
FA C24:0 (weight% of Fatty Acid Methyl Esters). Serum	wFA C24:0	w%	0.35	0.88	0.61	0.63	ns	3.7%	3.8%
FA C24:1 (weight% of Fatty Acid Methyl Esters). Serum	wFA C24:1	w%	0.64	1.65	1.11	1.19	****	4.7%	5%
FA C22:5 n-3 (weight% of Fatty Acid Methyl Esters). Serum	wFA C22:5 n-3	w%	0.26	0.74	0.52	0.47	****	4.3%	4.3%
FA C22:6 n-3 (weight% of Fatty Acid Methyl Esters). Serum	wFA C22:6 n-3	w%	0.68	3.49	1.97	2.21	****	3%	5.2%

Table 35: Summary of all blood variables

Variable	Biomarker	Men	Women
Alcohol	Adenosine Deaminase	*	ns
Alcohol	Artemin	*	ns
Alcohol	Delta and Notch-like epidermal growth factor-related receptor	***	**
Alcohol	Fibroblast growth factor 19	*	ns
Alcohol	Fibroblast growth factor 21	**	ns
Alcohol	Interleukin-33	*	ns
Alcohol	Osteoprotegerin	*	ns
Alcohol	Oncostatin-M	*	*
Alcohol	TNF-beta	*	ns
Alcohol	Tumor necrosis factor ligand superfamily member 14	*	ns
Alcohol	Tumor necrosis factor	**	*
Alcohol	CUB domain-containing protein 1	ns	**
Alcohol	Cystatin D	ns	*
Alcohol	C-X-C motif chemokine 6	ns	*
Alcohol	C-X-C motif chemokine 9	ns	*
Alcohol	Fibroblast growth factor 5	ns	***
Alcohol	Glial cell line-derived neurotrophic factor	ns	*
Alcohol	Interleukin-10	ns	*
Alcohol	Interleukin-20	ns	**
Alcohol	Interleukin-4	ns	*
Alcohol	Leukemia inhibitory factor receptor	ns	**
Alcohol	Monocyte chemotactic protein 3	ns	*
Alcohol	Monocyte chemotactic protein 4	ns	*
Alcohol	Matrix metalloproteinase-10	ns	*
Alcohol	Neurotrophin-3	ns	*
Alcohol	Stem cell factor	ns	*
Alcohol	Signaling lymphocytic activation molecule	ns	**
Alcohol	TNF-related activation-induced cytokine	ns	**
Alcohol	Urokinase-type plasminogen activator	ns	***
BMICategorical	C-C motif chemokine 3	****	*
BMICategorical	C-C motif chemokine 4	**	*
BMICategorical	CUB domain-containing protein 1	****	****
BMICategorical	Macrophage colony-stimulating factor 1	**	***
BMICategorical	Delta and Notch-like epidermal growth factor-related receptor	*	***
BMICategorical	Fibroblast growth factor 19	*	ns
BMICategorical	Fibroblast growth factor 21	***	*
BMICategorical	Fibroblast growth factor 5	*	ns
BMICategorical	Glial cell line-derived neurotrophic factor	***	**
BMICategorical	Hepatocyte growth factor	****	****
BMICategorical	Interleukin-18	****	***
BMICategorical	Interleukin-18 receptor 1	****	****
BMICategorical	Interleukin-4	*	ns
BMICategorical	Interleukin-6	****	****
BMICategorical	Interleukin-7	**	**
BMICategorical	Monocyte chemotactic protein 3	****	****
BMICategorical	Monocyte chemotactic protein 4	*	****
BMICategorical	Matrix metalloproteinase-1	***	ns
BMICategorical	Oncostatin-M	**	*
BMICategorical	Stem cell factor	****	ns
BMICategorical	Tumor necrosis factor receptor superfamily member 9	***	ns
BMICategorical	Tumor necrosis factor ligand superfamily member 14	*	ns
BMICategorical	Vascular endothelial growth factor A	**	****
BMICategorical	Caspase-8	ns	**
BMICategorical	C-C motif chemokine 25	ns	*
BMICategorical	T-cell surface glycoprotein CD5	ns	*
BMICategorical	Fractalkine	ns	**
BMICategorical	C-X-C motif chemokine 5	ns	*
BMICategorical	Interleukin-10 receptor subunit beta	ns	***
BMICategorical	Interleukin-17C	ns	*
BMICategorical	Interleukin-2	ns	*
BMICategorical	Monocyte chemotactic protein 1	ns	*
BMICategorical	Neurotrophin-3	ns	*
BMICategorical	TNF-related apoptosis-inducing ligand	ns	**
BMICategorical	TNF-related activation-induced cytokine	ns	*

Table 36: Biomarkers that are statistically significant for either men or women (1 of 8)

Variable	Biomarker	Men	Women
CheeseFrequency	Eotaxin	*	ns
CheeseFrequency	Leukemia inhibitory factor	*	*
CheeseFrequency	Matrix metalloproteinase-1	*	*
CheeseFrequency	Beta-nerve growth factor	ns	*
CheeseFrequency	Macrophage colony-stimulating factor 1	ns	*
CheeseFrequency	Fractalkine	ns	*
CheeseFrequency	Stem cell factor	ns	**
ChocolateFrequency	Eukaryotic translation initiation factor 4E-binding protein 1	**	ns
ChocolateFrequency	Interleukin-33	*	ns
ChocolateFrequency	C-C motif chemokine 3	ns	*
ChocolateFrequency	Interleukin-17A	ns	*
ChocolateFrequency	Interleukin-2	ns	**
ChocolateFrequency	Leukemia inhibitory factor receptor	ns	***
ChocolateFrequency	Stem cell factor	ns	*
ChocolateFrequency	SIR2-like protein 2	ns	*
ChocolateFrequency	STAM-binding protein	ns	*
D_NasalCarrier	Adenosine Deaminase	*	ns
D_NasalCarrier	Brain-derived neurotrophic factor	*	ns
D_NasalCarrier	Macrophage colony-stimulating factor 1	*	ns
D_NasalCarrier	Glial cell line-derived neurotrophic factor	*	ns
D_NasalCarrier	Interleukin-10 receptor subunit beta	*	ns
D_NasalCarrier	Interleukin-5	*	ns
D_NasalCarrier	Monocyte chemotactic protein 1	*	ns
D_NasalCarrier	Tumor necrosis factor receptor superfamily member 9	*	ns
D_NasalCarrier	Artemin	ns	*
D_NasalCarrier	Natural killer cell receptor 2B4	ns	*
D_NasalCarrier	CUB domain-containing protein 1	ns	*
D_NasalCarrier	C-X-C motif chemokine 10	ns	*
D_NasalCarrier	Signaling lymphocytic activation molecule	ns	*
D_ThroatCarrier	Caspase-8	**	ns
D_ThroatCarrier	C-C motif chemokine 19	*	ns
D_ThroatCarrier	Eukaryotic translation initiation factor 4E-binding protein 1	*	ns
D_ThroatCarrier	Monocyte chemotactic protein 2	*	ns
D_ThroatCarrier	SIR2-like protein 2	*	ns
D_ThroatCarrier	STAM-binding protein	*	ns
D_ThroatCarrier	C-C motif chemokine 25	ns	*
D_ThroatCarrier	Natural killer cell receptor 2B4	ns	*
D_ThroatCarrier	Fractalkine	ns	*
D_ThroatCarrier	Glial cell line-derived neurotrophic factor	ns	**
D_ThroatCarrier	Interleukin-15 receptor subunit alpha	ns	*
D_ThroatCarrier	Interleukin-1 alpha	ns	*
D_ThroatCarrier	Tumor necrosis factor	ns	*
D_ThroatCarrier	TNF-related apoptosis-inducing ligand	ns	**
D_ThroatCarrier	Tumor necrosis factor	ns	*
D_ThroatCarrier	Urokinase-type plasminogen activator	ns	*

Table 37: Biomarkers that are statistically significant for either men or women (2 of 8)

Variable	Biomarker	Men	Women
DairyFrequency	Axin-1	*	ns
DairyFrequency	Natural killer cell receptor 2B4	*	ns
DairyFrequency	T cell surface glycoprotein CD6 isoform	**	ns
DairyFrequency	Protein S100-A12	*	ns
DairyFrequency	Fibroblast growth factor 23	**	ns
DairyFrequency	Interferon gamma	*	ns
DairyFrequency	Interleukin-13	*	ns
DairyFrequency	Interleukin-18 receptor 1	**	ns
DairyFrequency	Interleukin-20	*	ns
DairyFrequency	Interleukin-20 receptor subunit alpha	***	ns
DairyFrequency	Matrix metalloproteinase-1	*	ns
DairyFrequency	Tumor necrosis factor	*	ns
DairyFrequency	Adenosine Deaminase	ns	*
DairyFrequency	Beta-nerve growth factor	ns	*
DairyFrequency	Fractalkine	ns	*
DairyFrequency	Interleukin-10 receptor subunit beta	ns	*
DairyFrequency	Leukemia inhibitory factor receptor	ns	*
DairyFrequency	Programmed cell death 1 ligand 1	ns	*
DairyFrequency	Stem cell factor	ns	*
E_NasalCarrier	Adenosine Deaminase	*	ns
E_NasalCarrier	C-C motif chemokine 20	*	ns
E_NasalCarrier	CUB domain-containing protein 1	*	ns
E_NasalCarrier	Macrophage colony-stimulating factor 1	*	ns
E_NasalCarrier	Interleukin-10 receptor subunit beta	**	ns
E_NasalCarrier	Interleukin-5	*	ns
E_NasalCarrier	Monocyte chemotactic protein 1	*	ns
E_NasalCarrier	Tumor necrosis factor receptor superfamily member 9	**	ns
E_NasalCarrier	Monocyte chemotactic protein 4	ns	*
E_ThroatCarrier	Artemin	**	ns
E_ThroatCarrier	C-C motif chemokine 20	**	ns
E_ThroatCarrier	C-C motif chemokine 4	ns	*
E_ThroatCarrier	Natural killer cell receptor 2B4	ns	*
E_ThroatCarrier	Fractalkine	ns	*
E_ThroatCarrier	Interleukin-13	ns	*
E_ThroatCarrier	Interleukin-17A	ns	*
E_ThroatCarrier	Interleukin-1 alpha	ns	*
E_ThroatCarrier	Interleukin-33	ns	*
E_ThroatCarrier	Interleukin-7	ns	*
E_ThroatCarrier	Latency-associated peptide transforming growth factor beta-1	ns	*
E_ThroatCarrier	TNF-beta	ns	*

Table 38: Biomarkers that are statistically significant for either men or women (3 of 8)

Variable	Biomarker	Men	Women
FatFishFrequency	C-C motif chemokine 20	**	*
FatFishFrequency	C-C motif chemokine 23	**	ns
FatFishFrequency	C-C motif chemokine 4	*	ns
FatFishFrequency	CD40L receptor	*	ns
FatFishFrequency	Fractalkine	**	*
FatFishFrequency	Hepatocyte growth factor	**	ns
FatFishFrequency	Interferon gamma	*	ns
FatFishFrequency	Interleukin-10 receptor subunit beta	**	ns
FatFishFrequency	Leukemia inhibitory factor receptor	*	ns
FatFishFrequency	Monocyte chemotactic protein 4	*	ns
FatFishFrequency	Osteoprotegerin	*	ns
FatFishFrequency	Stem cell factor	****	ns
FatFishFrequency	Latency-associated peptide transforming growth factor beta-1	*	ns
FatFishFrequency	Tumor necrosis factor	**	ns
FatFishFrequency	Caspase-8	ns	*
FatFishFrequency	Interleukin-20	ns	*
FatFishFrequency	TNF-beta	ns	*
FatFishFrequency	Tumor necrosis factor ligand superfamily member 14	ns	*
FruitJuiceFrequency	Beta-nerve growth factor	**	ns
FruitJuiceFrequency	Eotaxin	ns	*
FruitJuiceFrequency	C-C motif chemokine 3	ns	*
FruitJuiceFrequency	C-C motif chemokine 4	ns	*
FruitJuiceFrequency	T cell surface glycoprotein CD6 isoform	ns	*
FruitJuiceFrequency	Leukemia inhibitory factor receptor	ns	*
FruitJuiceFrequency	Neurotrophin-3	ns	****
FruitJuiceFrequency	Stem cell factor	ns	**
FruitJuiceFrequency	Urokinase-type plasminogen activator	ns	*
FruitsFrequency	C-C motif chemokine 3	**	ns
FruitsFrequency	Natural killer cell receptor 2B4	**	ns
FruitsFrequency	Interleukin-13	***	*
FruitsFrequency	Osteoprotegerin	*	ns
FruitsFrequency	C-C motif chemokine 20	ns	*
FruitsFrequency	T-cell surface glycoprotein CD5	ns	*
FruitsFrequency	Interleukin-10 receptor subunit alpha	ns	*
FruitsFrequency	Interleukin-15 receptor subunit alpha	ns	*
FruitsFrequency	Interleukin-24	ns	*
FruitsFrequency	Interleukin-2 receptor subunit beta	ns	*
FruitsFrequency	Monocyte chemotactic protein 2	ns	*
FruitsFrequency	Programmed cell death 1 ligand 1	ns	*
FruitsFrequency	TNF-beta	ns	*
GeneralHealth	Brain-derived neurotrophic factor	**	ns
GeneralHealth	Caspase-8	*	ns
GeneralHealth	Interleukin-10 receptor subunit alpha	*	ns
GeneralHealth	Interleukin-17C	*	ns
GeneralHealth	Leukemia inhibitory factor	***	ns
GeneralHealth	Monocyte chemotactic protein 2	*	ns
GeneralHealth	Osteoprotegerin	*	ns
GeneralHealth	Vascular endothelial growth factor A	*	ns
GeneralHealth	Axin-1	ns	*
GeneralHealth	Delta and Notch-like epidermal growth factor-related receptor	ns	**
GeneralHealth	Eukaryotic translation initiation factor 4E-binding protein 1	ns	*
GeneralHealth	Interleukin-5	ns	*
GeneralHealth	Matrix metalloproteinase-1	ns	**
GeneralHealth	SIR2-like protein 2	ns	*
GeneralHealth	STAM-binding protein	ns	*
GeneralHealth	Urokinase-type plasminogen activator	ns	*

Table 39: Biomarkers that are statistically significant for either men or women (4 of 8)

Variable	Biomarker	Men	Women
HighSchool	Adenosine Deaminase	**	ns
HighSchool	C-C motif chemokine 25	*	*
HighSchool	Cystatin D	*	ns
HighSchool	Fractalkine	***	*
HighSchool	C-X-C motif chemokine 10	***	ns
HighSchool	Delta and Notch-like epidermal growth factor-related receptor	****	ns
HighSchool	Eukaryotic translation initiation factor 4E-binding protein 1	*	ns
HighSchool	Fibroblast growth factor 21	****	****
HighSchool	Fibroblast growth factor 23	****	ns
HighSchool	Fms-related tyrosine kinase 3 ligand	*	ns
HighSchool	Interleukin-12 subunit beta	*	ns
HighSchool	Interleukin-15 receptor subunit alpha	*	ns
HighSchool	Interleukin-18	*	ns
HighSchool	Interleukin-18 receptor 1	*	**
HighSchool	Interleukin-2	***	*
HighSchool	Interleukin-7	*	ns
HighSchool	Leukemia inhibitory factor	*	ns
HighSchool	Leukemia inhibitory factor receptor	***	*
HighSchool	Monocyte chemotactic protein 1	*	***
HighSchool	Osteoprotegerin	****	ns
HighSchool	Programmed cell death 1 ligand 1	*	ns
HighSchool	Tumor necrosis factor receptor superfamily member 9	*	*
HighSchool	Tumor necrosis factor ligand superfamily member 14	***	ns
HighSchool	TNF-related activation-induced cytokine	*	ns
HighSchool	Urokinase-type plasminogen activator	***	**
HighSchool	C-C motif chemokine 20	ns	*
HighSchool	C-C motif chemokine 4	ns	**
HighSchool	Fibroblast growth factor 19	ns	**
HighSchool	Interleukin-20	ns	*
HighSchool	Interleukin-6	ns	**
HighSchool	Monocyte chemotactic protein 4	ns	*
HighSchool	Matrix metalloproteinase-1	ns	*
HighSchool	Stem cell factor	ns	**
HighSchool	Transforming growth factor alpha	ns	*
HighSchool	Thymic stromal lymphopoietin	ns	*
LeanFishFrequency	CD40L receptor	*	ns
LeanFishFrequency	Eukaryotic translation initiation factor 4E-binding protein 1	*	ns
LeanFishFrequency	Fibroblast growth factor 23	*	ns
LeanFishFrequency	Interleukin-4	*	ns
LeanFishFrequency	Interleukin-6	*	ns
LeanFishFrequency	SIR2-like protein 2	*	ns
LeanFishFrequency	Urokinase-type plasminogen activator	**	ns
LeanFishFrequency	Vascular endothelial growth factor A	*	ns
LeanFishFrequency	C-C motif chemokine 28	ns	*
LeanFishFrequency	C-X-C motif chemokine 11	ns	**
LeanFishFrequency	Fibroblast growth factor 21	ns	**
LeanFishFrequency	Interleukin-18	ns	*
LeanFishFrequency	Matrix metalloproteinase-10	ns	*

Table 40: Biomarkers that are statistically significant for either men or women (5 of 8)

Variable	Biomarker	Men	Women
ScreenTime	Fibroblast growth factor 19	*	ns
ScreenTime	CUB domain-containing protein 1	ns	*
ScreenTime	Interleukin-1 alpha	ns	**
ScreenTime	Leukemia inhibitory factor receptor	ns	*
ScreenTime	Transforming growth factor alpha	ns	*
ScreenTime	Tumor necrosis factor ligand superfamily member 14	ns	*
Smoke	Fibroblast growth factor 23	*	ns
Smoke	Interleukin-12 subunit beta	*	ns
Smoke	Interleukin-1 alpha	**	ns
Smoke	Interleukin-7	*	*
Smoke	Matrix metalloproteinase-10	***	ns
Smoke	Tumor necrosis factor	**	*
Smoke	Adenosine Deaminase	ns	**
Smoke	Eotaxin	ns	*
Smoke	CUB domain-containing protein 1	ns	*
Smoke	Cystatin D	ns	*
Smoke	C-X-C motif chemokine 9	ns	**
Smoke	Delta and Notch-like epidermal growth factor-related receptor	ns	***
Smoke	Fibroblast growth factor 21	ns	****
Smoke	Glial cell line-derived neurotrophic factor	ns	*
Smoke	Interleukin-18 receptor 1	ns	*
Smoke	Leukemia inhibitory factor receptor	ns	****
Smoke	Stem cell factor	ns	****
Smoke	Urokinase-type plasminogen activator	ns	****
Snuff	Adenosine Deaminase	**	ns
Snuff	Cystatin D	**	ns
Snuff	Fractalkine	***	ns
Snuff	Fibroblast growth factor 21	**	**
Snuff	Fibroblast growth factor 23	*	ns
Snuff	Interleukin-17C	*	ns
Snuff	Interleukin-1 alpha	**	ns
Snuff	Interleukin-22 receptor subunit alpha-1	*	ns
Snuff	Oncostatin-M	*	ns
Snuff	Stem cell factor	**	***
Snuff	Tumor necrosis factor	*	ns
Snuff	Tumor necrosis factor ligand superfamily member 14	*	ns
Snuff	CD40L receptor	ns	**
Snuff	Macrophage colony-stimulating factor 1	ns	**
Snuff	C-X-C motif chemokine 9	ns	*
Snuff	Glial cell line-derived neurotrophic factor	ns	***
Snuff	Interleukin-18 receptor 1	ns	**
Snuff	Leukemia inhibitory factor receptor	ns	*
Snuff	Urokinase-type plasminogen activator	ns	***
Snuff	Vascular endothelial growth factor A	ns	*

Table 41: Biomarkers that are statistically significant for either men or women (6 of 8)

Variable	Biomarker	Men	Women
SportsLeisure	Adenosine Deaminase	**	***
SportsLeisure	C-C motif chemokine 19	**	ns
SportsLeisure	C-C motif chemokine 4	*	ns
SportsLeisure	Delta and Notch-like epidermal growth factor-related receptor	**	*
SportsLeisure	Fibroblast growth factor 21	****	****
SportsLeisure	Fibroblast growth factor 23	*	ns
SportsLeisure	Leukemia inhibitory factor receptor	*	ns
SportsLeisure	Urokinase-type plasminogen activator	***	**
SportsLeisure	Vascular endothelial growth factor A	*	ns
SportsLeisure	C-C motif chemokine 23	ns	*
SportsLeisure	C-X-C motif chemokine 1	ns	*
SportsLeisure	Interleukin-6	ns	***
SugarDrinkFrequency	Eukaryotic translation initiation factor 4E-binding protein 1	**	ns
SugarDrinkFrequency	Interleukin-10 receptor subunit alpha	*	ns
SugarDrinkFrequency	C-C motif chemokine 3	ns	*
SugarDrinkFrequency	Fractalkine	ns	*
SugarDrinkFrequency	Interleukin-12 subunit beta	ns	*
SugarDrinkFrequency	Monocyte chemotactic protein 2	ns	*
SugarDrinkFrequency	Signaling lymphocytic activation molecule	ns	**
SugarDrinkFrequency	TNF-beta	ns	*
SugarDrinkFrequency	Thymic stromal lymphopoietin	ns	**
SugarJuiceFrequency	C-C motif chemokine 25	*	ns
SugarJuiceFrequency	Interleukin-5	*	ns
SugarJuiceFrequency	Neurturin	*	ns
SugarJuiceFrequency	Signaling lymphocytic activation molecule	*	ns
SugarJuiceFrequency	C-C motif chemokine 3	ns	**
SugarJuiceFrequency	T cell surface glycoprotein CD6 isoform	ns	*
SugarJuiceFrequency	Leukemia inhibitory factor receptor	ns	*
SummerTransport	C-C motif chemokine 19	*	ns
SummerTransport	C-C motif chemokine 28	**	ns
SummerTransport	Eukaryotic translation initiation factor 4E-binding protein 1	*	*
SummerTransport	Interleukin-24	*	ns
SummerTransport	Interleukin-33	*	**
SummerTransport	Interleukin-4	****	ns
SummerTransport	Monocyte chemotactic protein 1	*	ns
SummerTransport	Axin-1	ns	*
SummerTransport	Caspase-8	ns	**
SummerTransport	C-C motif chemokine 3	ns	*
SummerTransport	CUB domain-containing protein 1	ns	*
SummerTransport	C-X-C motif chemokine 11	ns	*
SummerTransport	Fibroblast growth factor 19	ns	*
SummerTransport	Hepatocyte growth factor	ns	*
SummerTransport	Interleukin-18	ns	**
SummerTransport	Interleukin-18 receptor 1	ns	*
SummerTransport	Interleukin-2	ns	*
SummerTransport	Matrix metalloproteinase-1	ns	*

Table 42: Biomarkers that are statistically significant for either men or women (7 of 8)

Variable	Biomarker	Men	Women
SweetenerDrinkFrequency	Fractalkine	*	ns
SweetenerDrinkFrequency	Urokinase-type plasminogen activator	*	ns
SweetenerDrinkFrequency	Caspase-8	ns	*
SweetenerDrinkFrequency	Interleukin-13	ns	*
SweetenerDrinkFrequency	Interleukin-22 receptor subunit alpha-1	ns	*
SweetenerDrinkFrequency	Monocyte chemotactic protein 2	ns	*
SweetenerDrinkFrequency	Monocyte chemotactic protein 3	ns	*
SweetenerDrinkFrequency	Neurotrophin-3	ns	****
SweetenerDrinkFrequency	Stem cell factor	ns	*
SweetenerDrinkFrequency	Tumor necrosis factor	ns	*
SweetenerDrinkFrequency	Thymic stromal lymphopoietin	ns	*
VegetablesFrequency	Caspase-8	*	ns
VegetablesFrequency	C-C motif chemokine 4	*	ns
VegetablesFrequency	Interleukin-4	**	ns
VegetablesFrequency	Interleukin-7	*	ns
VegetablesFrequency	Stem cell factor	**	ns
VegetablesFrequency	Tumor necrosis factor	*	ns
VegetablesFrequency	Eotaxin	ns	*
VegetablesFrequency	C-C motif chemokine 19	ns	*
VegetablesFrequency	Fractalkine	ns	*
WaterFrequency	Interleukin-4	**	ns
WaterFrequency	Monocyte chemotactic protein 2	*	ns
WaterFrequency	Urokinase-type plasminogen activator	*	ns
WaterFrequency	Brain-derived neurotrophic factor	ns	*
WaterFrequency	Fibroblast growth factor 5	ns	*
WaterFrequency	Interleukin-2 receptor subunit beta	ns	*
WinterTransport	C-C motif chemokine 19	**	ns
WinterTransport	Eukaryotic translation initiation factor 4E-binding protein 1	*	ns
WinterTransport	Fms-related tyrosine kinase 3 ligand	*	ns
WinterTransport	Interleukin-24	*	ns
WinterTransport	Interleukin-4	*	ns
WinterTransport	Monocyte chemotactic protein 2	*	ns
WinterTransport	TNF-beta	*	ns
WinterTransport	Tumor necrosis factor receptor superfamily member 9	*	ns
WinterTransport	Caspase-8	ns	*
WinterTransport	Fibroblast growth factor 19	ns	*
WinterTransport	Fibroblast growth factor 5	ns	*
WinterTransport	Hepatocyte growth factor	ns	**
WinterTransport	Interleukin-22 receptor subunit alpha-1	ns	*
WinterTransport	Matrix metalloproteinase-1	ns	*
WinterTransport	Matrix metalloproteinase-10	ns	*
WinterTransport	Transforming growth factor alpha	ns	*
WinterTransport	Latency-associated peptide transforming growth factor beta-1	ns	**

Table 43: Biomarkers that are statistically significant for either men or women (8 of 8)

8 Change History

This section helps keeping track of all the changes done in the document. Here is where all the TODO notes go when they are resolved. And you would find something like this so it is not repeated again

0.1

Something changed for the first time, and here is why it happens

0.2

The change was bad. Somebody suggested that we undo the change and just clarify the second paragraph.

0.22

We decided that dogs should not also be included in the results part, the article will talk only about humans from now on.